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Mismatched base pairs are ubiquitous in more than 30 hereditary disorders whose origin 
can be traced to unstable repeating sequences in genomic DNA. For instance, non-Watson–
Crick T–T mismatch base pairs flanked by G–C base pairs appear in myotonic dystrophy type 
1 (DM1), which is caused by the expansion of CTG trinucleotide repeats (TNR) in the 3’-
untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. Extensive 
efforts have made it possible to elucidate its pathogenesis and mechanism of action. In this 
regard, numerous compounds have been developed that target the toxic repeating CUG RNA 
transcript (r(CUG)exp) and inhibit its sequestration of key pre-mRNA splicing proteins, such as 
MBNL1. Indeed, since we reported our first ligand JFA in 2009, our group has been at the 
forefront in discovering ligands that specifically bind U–U mismatches and can potentially be 
used as therapeutics. More recently, we have started to focus our efforts to discover molecules 
that target the parent CTG expanded repeats (d(CTG)exp) in hopes to develop a more promising 
therapeutic. A brief overview of targeting DNA, DNA mismatches, DM1 and our ligands is 
given in Chapter 1. 
A previous anisotropy screen in our lab of ligands that inhibit the MBNL1–r(CUG)exp 
complex identified a novel lead pyrroloquinazoline compound. However, as we will see in 
Chapter 2, further investigation revealed that it was selective for T–T mismatches. 
Interestingly, we noted that mode of binding toward CTG mismatched sites appeared to be 
cooperative. Due to its limited water solubility, we attempted to develop further derivatives. 
We took into consideration these observations to develop and improve our acridine-base 
ligands in the last chapter. 
To further improve the affinity and selectivity of our acridine-based ligands, we proceeded 
to develop a series of enforced stacked intercalators. Our first approach involved utilizing a 
larger mismatch-recognition diaminopurine unit, as the described in the first part of Chapter 3. 
However, although selective for T–T and C–C mismatches, its nonspecific binding was not 
improved. Finally, we employed a macrocyclic design, and developed a small library of 
macrocycles. We showed that these ligands selectively bind to CTG trinucleotide repeats in 
DNA with negligible nonspecific binding to duplex DNA. In addition, they were about twice 
as effective and selective in inhibiting transcription than the control. Lastly, we discovered that 
the macrocyclic structure design of our ligands did not necessarily correlate with a reduction 
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in their cytotoxicity in HeLa cells, as we had previously hypothesized. The synthesis, 
biophysical studies, and in vitro activity of these macrocyclic ligands are described in the 
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1.1. Targeting Nucleic Acids with Small Molecules Mismatches 
DNA and RNA targeting with small molecules represents a well-established area of 
research and is of great academic and pharmaceutical interest. One of the major turning points 
in the area of DNA binding with small molecules was when Lerman hypothesized the concept 
of the intercalation of acridine derivatives (e.g., proflavine) in DNA in 1961,1 for which 
seminal crystallographic studies were reported in the late 1970s that showed DNA could 
elongate to allow space to “sandwich” an acridine molecule between two base pairs.2,3 The 
concept of binding DNA as a therapeutic strategy was evident from the onset, inspiring 
research on natural product intercalators such as the powerful anticancer drug actinomycin D.4 
Although there are many other natural products that bind DNA (e.g., echinomycin5, 
distamycin A6), synthesizing and developing small molecules in the laboratory that recognize 
specific nucleotide sequences has remained a challenge.7 Indeed, the majority of small 
molecules bind non- or poorly specifically and through two broad major and well-characterized 
binding modes: intercalation or groove binding.8,9 Intercalators typically contain an aromatic 
core that facilitates binding by insertion between base pairs, and more complex intercalators 
(Figure 1) contain further functional groups that facilitate groove binding. Notably, 
intercalators that are highly selective towards complex DNA structures such as triplexes10 and 
quadruplexes11 have been studied in recent years. In addition, intercalation reduces the natural 
DNA helical twist (e.g., ethidium untwists DNA by 26º).12 This distortion prevents 




Figure 1. Examples of intercalators. 
On the other hand, groove binders are typically positively-charged Instead of the fused 
aromatic ring architecture seen in intercalators, groove binders are typically positively charged, 
crescent-shaped molecules constituted of linked aromatic rings (Figure 2a).14 Some well-
known groove binders include Hoechst 33258, netropsin and berenil.12 Perhaps the most well-
known synthetic sequence-specific binders are imidazole-pyrrole ligands developed by 
Dervan, with affinities in the nano- to picomolar range (Figure 2b).15-17 These groove binders 
Figure 2. (a) Chemical structure of groove binder netropsin. (b) Model for the complex formed between hexapeptide 
Dervan-type groove binder 1 and a DNA duplex with a 5’-TGTTA-3’ site. Circles with dots represent lone pairs of 
N(3) of purines and O(2) of pyrimidines. Circles containing an H represent the N(2) hydrogen of guanine. Reproduced 


























































were able to specifically discriminate A–T and T–A base pairs by utilizing pyrrole–
hydroxypyrrole and hydroxypyrrole-pyrrole pairings, respectively. 
Several small molecules that specifically target nucleic acids have been studied and shown 
to interfere with DNA processes such as replication, transcription, translation, and also impact 
cell proliferation.9 Likewise, molecules that bind RNA exhibit similar effects such as 
interfering with translation by binding mRNA directly.18 Accordingly, the design and 
discovery of small molecules that bind DNA and RNA defects, such as mismatches and abasic 
sites, in a selective and specific fashion is key to the development of DNA-targeting drugs (and 
the side-effects of existing drugs), but still remains an important challenge.19 (For an excellent 
book on this topic, see Small Molecule DNA and RNA Binders: From Synthesis to Nucleic Acid 
Complexes.7) 
1.2. Binding and Recognition of DNA Mismatches 
DNA mismatches are defects that occur when two non-complementary bases are aligned 
in the same base-pair step of a duplex. Mismatches can appear during replication, formation of 
heteroduplexes during recombination, and even spontaneous deamination of nucleobases.18 
Damage to DNA bases can also be caused by physical factors (e.g., UV radiation) and 
environmental damaging chemicals (e.g., alkylating agents), and can lead to the formation of 
mismatched base pairs followed by mutagenesis, dysfunctions and diseases.20 If uncorrected, 
(a) (b) 
Figure 3. Chemical structure of (a) naphthyridine dimer 2 and (b) [Rh(bpy)2(chrysi)]3+ complex designed for 















DNA mismatches can ultimately give rise to genetic mutations and disease states.21 
Consequently, the MutS protein of the mismatch repair (MMR) system, perhaps the best-
characterized DNA repair system,22 recognizes and corrects damaged sites with excellent 
efficiency and specificity (up to 1000-fold higher affinity compared to normal duplex).23  
In efforts to gain insight into natural nucleotide mismatch recognition systems, the last few 
decades have seen an enormous spike in the development of small molecules that site-
specifically recognize mismatches, as well as the characterization of mismatches. Indeed, the 
structures of most mismatched base pairs have been reported (X-ray crystallography or NMR 
studies in solution), with interesting features such as wobble pairs, protonated bases, unusual 
base tautomers, and others.24 Pioneering efforts to develop mismatch-selective ligands include 
the work by Barton, who developed the intercalating rhodium(III) complex25 
[Rh(bpy)2(chrysi)]3+ and a series of derivatives with excellent mismatch selectivity;26,27 and 
also the work by Nakatani, who has developed a series of dimeric naphthyridine intercalators 
capable of hydrogen-bonding with mismatched nucleobases specifically in a triplet pattern due 
to their unique mode of binding (Figure 3).28 In addition, as will be discussed in Chapter 3, 
cyclobisintercalators have also been studied to selectively bind DNA mismatches, an area 
pioneered by Lehn and Teulade-Fichou.29-31 
Besides their high potential as therapeutic candidates or diagnostic tools in fields such as 
molecular genetics, mismatch-selective small molecules also offer potential applications to 
manipulate and analyze DNA in vitro. In essence, to achieve efficient function, these small 
molecules must be able to target specific mismatched sites in an “ocean” of normal Watson-
Crick base pairs. Undoubtedly, Nature is once again way ahead of us. 
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1.3. Trinucleotide Repeat Diseases 
Mismatched base pairs are ubiquitous in more than 30 hereditary disorders whose origin 
can be traced to unstable repeating nucleotide sequences in genomic DNA. Although the 
majority of expanded repeats consist of trinucleotide sequences in the form (CXG)exp (X = any 
nucleotide), there are a some with tetra-, penta-, and even dodecameric repeats.32 DNA 
trinucleotide repeats are actually common within the human genome; however, it is the 
expansion of these repeats that alters gene expression and human cells, which leads to genetic 
disorders. Some of the more well-known trinucleotide repeat (TNR) expansion diseases 
include Fragile-X Syndrome (CGG), Huntington’s disease (CAG), Friedreich’s ataxia (GAA) 
and myotonic dystrophy (CTG).33-35 Each disease has a unique base repeat sequence, either in 
a coding or noncoding region of DNA, and their location in the genome. In contrast to static 
mutations, which are maintained in somatic tissues and stably passed down from generation to 
generation, mismatch repeat mutations continue to expand in length within tissues and 
generations.36 The length of the repeat tract is known to correlate with disease severity and 
genetic anticipation (i.e., age of onset). So far, no cures or approved treatments are available 
for these diseases, only palliative therapeutics to treat their symptoms. 
1.4. Myotonic Dystrophy 
Discovered in 1992, myotonic dystrophy type 1 (DM1) is one of the two major types of 
myotonic dystrophy, which is the most common form of adult muscular dystrophy, and affects 
about 1 in 8,000 people worldwide.37-39 As with the other TNR diseases, there are currently no 
cures or treatments for this disease; only medications to alleviate symptoms. Patients suffer 
from progressive muscle weakness, sustained muscle contractions, cardiac defects, and other 
neuromuscular problems.37 
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1.4.1. Disease Mechanism 
DM1 is caused by the unstable expansion of CTG trinucleotide repeats (d(CTG)exp) (50 to 
>2,000 repeats) in the 3’-untranslated region of the dystrophia myotonica protein kinase 
(DMPK) gene in  chromosome 19q13 (Figure 4).34,36,38 In fact, CTG•CAG trinucleotide repeat 
expansions at distinct chromosomal loci is the mutation present in several other neurological 
diseases such as Huntington’s disease (HD), and many forms of spinocerebellar ataxia 
(SCA).40,41 Like other TNR expansion diseases, repeat length correlates directly with DM1 
disease severity and inversely with the age of onset – a phenomenon termed anticipation.38 
The expansion of trinucleotide repeats is a complicated process believed to occur during 
the transient exposure of single DNA strands, such as during replication, recombination, 
transcription, and by multiple repair mechanisms.33,34,42 Most models agree that the repetitive 
nature of dsDNA promote the formation of “slipped-stranded” DNA conformation through 
denaturation and renaturation.35,43 In the case of DM1, it is thought that the transcription of 
CTG•CAG repeats, by transiently exposing single DNA strands, allows long CAG and CTG 
Figure 4. Schematic overview of the molecular basis for DM1. 
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repeat tracts to form abnormal secondary structures, such as d(CAG)exp slipped-strand DNA, 
and d(CTG)exp hairpins structures in which non-Watson–Crick T–T mismatch base pairs 
flanked by G–C base pairs.42,44 The formation of these stable unusual secondary structures 
kinetically “trap” the expanded repeating unit, which engages in several DNA repair processes 
and stall various DNA polymerases.42,44 This results in the misalignment of repetitive DNA 
strands, causing expansions or contractions of the repeats.45 
Studies support a gain-of-function mechanism of the expanded RNA transcript. Upon 
transcription of the d(CTG)exp strands, the repeating r(CUG)exp folds into an extended hairpin 
that contains multiple copies of 5’-CUG/3’-GUC motifs, which bind muscleblind-like 1 
protein (MBNL1) and form ribonuclear foci (Figure 4).46 The r(CUG)exp can also cause 
aberrant activation of protein kinase C (PKC), which leads to hyperphosphorylation, 
stabilization, and up-regulation of the CUG-binding protein 1 (CUGBP1).47 These two proteins 
are coregulators of various alternative splicing transitions, and their disruption has been 
correlated with dysregulation of pre-mRNA splicing, some of which are known to directly 
result in disease symptoms such as insulin insensitivity (IR splicing), myotonia (CLCN1 
splicing), and cardiac defects (cTNT splicing).48 Likewise, it was shown that r(CUG)exp 
disrupted the translation of the MEF2 protein, which affects multiple levels of mRNA and 
miRNA in heart tissues.49 In addition, other r(CUG)exp-induced toxic pathways have recently 
been suggested to be involved in the DM1 pathogenesis. Notably, the bidirectional 
transcription of the CTG•CAG repeats produce r(CAG)exp and r(CUG)exp transcripts,50 which 
further undergo repeat-associated non-ATG (RAN) translation and make multiple toxic 
homopeptides.51 Further, it was shown that r(CUG)exp disrupted the translation of the MEF2 
protein, which affects various levels of mRNA and microRNA in heart tissues. 
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1.4.2. Therapeutic Strategies for DM1 
One therapeutic approach for DM1 is to disrupt the harmful interactions between MBNL1 
and r(CUG)exp by using small molecules. This was shown in a groundbreaking study by 
Swanson in which the overexpression of MBNL1 in a DM1 mouse model resulted in the 
reduction of myotonia and restored the normal adult-splicing patterns for 4 pre-mRNAs.52 
Consequently, Miller reported three lead compounds from a dynamic combinatorial library 
(DCL) screening for synthetic RNA-binding ligands that inhibit MBNL1–r(CUG)exp 
interaction.53 Additionally, Berglund discovered that pentamidine disrupted the MBNL1–
r(CUG)exp complex and reversed the missplicing of several pre-mRNAs in HeLa cells.54 
Alternatively, another potential strategy is to target the CTG•CAG trinucleotide repeat 
expansions. Although a drug that targets the toxic r(CUG)exp would alleviate the disease 
symptoms, there are some drawbacks to this approach. Importantly, 1) the r(CUG)exp 
transcripts would be continuously produced as the parent DNA is still present, 2) the patient’s 
expanded CTG repeats would continue to expand with time and could potentially result in 
needing larger quantities of therapeutics, and 3) continuation of disease progression continues 
further transmission between generations with a reduced age of onset and a significantly more 
severe form of the disease.32,35,36 
Although multiple processes cause the expansion of TNR and their detailed mechanisms 
are not yet known,36,55-57 one of the replication models for repeat instability suggests that 
formation of a stable secondary structure by a repetitive run in the lagging-strand template 
stalls lagging-strand synthesis and that repeat contractions occur if a DNA polymerase 
involved in repair of the gap skips the structured portion of the lagging-strand template.34,36,43 
Thus, developing a small molecule therapeutic that selectively binds hairpin d(CTG)exp or 
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CTG•CAG triplet repeats in DNA and can inhibit its transcription or induce its contraction 
could potentially be a powerful strategy to cure the disease, although it would be an especially 
challenging goal because multiple processes cause the expansion and their detailed 
mechanisms are not yet known.36,55-57 As of now, there are only a handful of  reports on small 
molecules that have induced contractions and decreased the rate of expansion of the CTG•CAG 
triplet repeat,58-60 and two reports that utilize CRISPR-Cas9 technology to contract CTG•CAG 
triplet repeats.57,61 
In line with this strategy, our group and others have developed small molecules that bind 
r(CUG)exp and inhibit the sequestration of MBNL1 (see Section 1.5 for an overview of ligands 
from our lab).52-54,62-72 
1.5. Development of Small Molecules in the Zimmerman Group 
In 2009, we reported a rationally-designed acridine-based intercalator (i.e., ligand JFA) 
with a triaminotriazine ring as a “Janus-wedge” recognition unit, resulting in very low 
micromolar affinity to CTG and CUG mismatched sites in DNA and RNA, respectively.62 This 
triaminotriazine unit is believed to interact with the mismatched thymine or uracil units through 
its two hydrogen bonding faces and allowing complementarity with the mismatches (Figure 
5). Indeed, subsequent biophysical studies and molecular dynamics simulations suggested a 


















































Figure 5. (a) Chemical structure of ligand JFA and its proposed Janus-wedge-type binding mode with 
mismatched base pairs (black) through hydrogen-bonding of the triaminotriazine unit (red). (b) Chemical structure 




















ring, while the acridine ring ultimately intercalates between the mismatch and the neighbor 
Watson-Crick base pair.73 Further derivatization64 and development of dimeric analogs65 was 
done to increase the ligand’s water solubility and inhibition potency.  
Due to the general cytotoxicity of intercalators and limited aqueous solubility, a second 
type of inhibitor was developed (ligand 3) with improved solubility and almost no 
cytotoxicity.63 This ligand contains a bisamidinium groove-binding motif, which was 
previously used by Butcher in 2011 for a ligand that binds to the stem-loop region of the HIV-
1 frameshift site (FS) RNA, an A-form helix similar to r(CUG)exp.74 Ligand 3 also contains 
two triaminotriazine units to increase the affinity and selectivity by the simultaneous 
recognition of two CUG mismatch sites. Indeed, foci reduction was observed with as little as 
5 µM of 3 in d(CTG)960-transfected HeLa cells. Ligand 3 was also shown to correct the 
misregulated splicing of IR transcript. Derivatives were developed that could intervene in 
multiple DM1 disease pathways,75 and dimerized through azide-alkyne “click” chemistry to 
produce a powerful inhibitor of the MBNL1–r(CUG)exp complex.76  In addition to finding new 
cores or scaffolds for the development of new novel types of inhibitors, as with our 
pyrroloquinazoline ligand in Chapter 2, we are also interested in to further enhancing and 





DISCOVERY OF A NEW DNA-BINDING LIGAND 
2.1. Introduction 
2.1.1. High Throughput Screening to Identify Lead Compounds for DM1 
One of the most widespread therapeutic approaches for DM1 has been to disrupt the 
harmful interactions between MBNL1 and r(CUG)exp by using small molecules. Disney and 
coworkers reported that small molecules that bind to MBNL1 induced splicing defects and 
DM1 disease phenotypes.48 Indeed, a major goal of our lab is to discover and develop low-
molecular weight therapeutic agents that target the toxic r(CUG)exp in DM1. Traditionally, we 
had utilized rational design to develop our lead compounds. We developed our first lead 
compound (JFA)62 based on the reported crystal structure of r(CUG)6 by Berglund in 2005.77 
Likewise, we developed our second-generation bisamidinium groove-binding ligand based on 
the reported NMR solution structure of an RNA frameshift site stimulator and its binding in 
the stem-loop region of the HIV-1 frameshift site (FS) RNA.74 Although rational design 
provides the freedom to custom-design small molecules, it is often a slow method to survey a 
large chemical space and discover new potential lead compounds. 
A high-throughput screen (HTS) of a library of small molecules is a powerful approach 
that would expedite the discovery and identification of possible lead compounds. In 2012, 
Austin and coworkers reported two assays that could be used orthogonally in a HTS fashion 
for the detection of ligands that inhibit the formation of the toxic MBNL1–r(CUG)exp 
complex.78 The assay utilizes biotinylated r(CUG)12 and MBNL1-His6 along with 
fluorescently labelled streptavidin and a fluorescently labelled anti-His6 antibody. When the 
MBNL1–r(CUG)exp complex forms, the two fluorophores form a fluorescence resonance 
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energy transfer (FRET) pair and time-resolved (TR)-FRET can be measured. A small molecule 
inhibitor of the complex would result in no TR-FRET signal. In 2013, Disney reported four 
lead compounds that were identified with this assay (Figure 6) and noted that 5 induced 
splicing defects of the IR and cTNT mini-genes towards a DM1-like phenotype, providing 




Figure 6. Small molecules that inhibit the formation of the MBNL1–r(CUG)12 complex as identified by the 
Disney group through a screen of the NIH’s MLPCN library. 
2.1.2. Lead Compound Discovery Through High Throughput Fluorescence Anisotropy 
Screening 
Previously in our lab, small molecule inhibitors were screened in efforts to discover and 
identify new lead compounds for DM1 therapeutics. Yen-Jun Ho tested the binding of several 
molecules to the MBNL1–r(CUG)exp complex using a HTS fluorescence anisotropy assay.79 
This technique was reported by Shapiro and coworkers in 2006 to discover small molecule 
inhibitors of the vigilin-vitellogenin mRNA complex.80 First described by Perrin in 1926, 
fluorescence polarization is based on the observation that when plane-polarized light  excites 
stationary fluorescent molecules, these will emit light back in a fixed plane. However, 
fluorophores usually undergo rotational diffusion more rapidly than the time required for light 
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the emitted light.  In contrast, when the fluorophore is bound to a larger molecule (e.g., a 
protein), the larger effective molecular volume causes the rotation to be slower. Light emission 
is more likely to be in the same plane as that during excitation and remain highly polarized. 
Thus, fluorescence anisotropy measures the loss of polarization of the light emitted from the 
fluorophore, which is affected by the rate of tumbling of the bound complex.  
The bound state should be much larger than the free state to obtain the best signal 
difference. Yen-Jun Ho used a r(CUG)6 with TAMRA attached to the 5’-end as the RNA 
construct, and GST-MBNL1N (56 kDa) as the protein.79 From over 140,000 compounds stored 
at the National Cancer Institute, the 1,597-compound Diversity Set III was chosen for the initial 
assay development based on pharmacologically desirable features and representation of novel 
pharmacophores, among others. The fluorescence anisotropy screen resulted in the 
identification of 14 hits, and following subsequent confirmatory EMSA assays for the 
displacement of radio-labeled r(CUG)12 and activity in the presence of competitor tRNA 
narrowed this to 4 lead compounds (Figure 7).79 Of these four compounds, ligand 11 showed 
the most promise and was investigated further due to its simpler synthetic scheme. 
 
































2.1.3. Ligand 11 Inhibits the MBNL1–CUG Complex 
One of the hits identified as a MBNL1–r(CUG)exp complex inhibitor was the 
pyrroloquinazoline ligand 11 (Figure 2.2), which, along with its derivatives, had been 
previously described as an inhibitor of dihydrofolate reductase in 1996 by Stables81 and 
assessed for antimalarial activities in 2005 by Lin.82 When studied with TAMRA-r(CUG)6 and 
GST-MBNL1N, ligand 11 exhibited an IC50 of 61 ± 15 µM with a calculated Ki of 15 ± 3 µM,79 
which were similar to other small molecule inhibitors (e.g., pentamidine54, IC50 = 58 ± 5 µM). 
These results provided preliminary promise that ligand 11 could be used as a lead compound 
to further derivatize and optimize as a r(CUG)exp binder. 
2.2. Discovery that Ligand 11 Binds d(CTG)2 
 As mentioned in Chapter 1, developing a small molecule therapeutic that targets the parent 
d(CTG)exp and could inhibit its transcription or lead to its contraction is another potential 
strategy to cure the disease, although fully detailed mechanisms are not yet known.36,55-57 This 
is potentially a step towards curing the disease rather than disrupting protein-RNA interactions. 
Thus, our group has recently decided to screen the binding capabilities of ligand 11 against 
other DNA mismatches to further assess its selectivity. 
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The pyrroloquinazoline ligand was synthesized from commercially available 5-
aminoindole. Condensation with dicyanamide to give the cyanoguanidine derivative 14 
occurred in excellent yield. Finally, ring closure to form the diaminopyrimidine ring was 
carried out with boron trifluoride etherate (Scheme 1). It is important to point out the structural 
and hydrogen-bonding similarities between ligand 11 and the triaminotriazine recognition unit 
used in ligand JFA.  
To test the binding properties and selectivity of ligand 11, isothermal titration calorimetry 
(ITC) experiments were performed with 10-base oligonucleotides: r(CUG)2, d(CTG)2, 
d(CAG)2, and dsDNA (Table 1). ITC allows ∆G°, ∆H°, and T∆S° for a ligand-receptor 
interaction to be determined by measuring stepwise changes in the enthalpy of interaction 
during the course of a titration experiment.83 To our surprise, ligand 11 was found to bind to 
d(CTG)2 with micromolar affinity (KD ~ 6 µM) but did not exhibit measurable binding to 
r(CUG)2 (Figure 8). Although this raised the question of how ligand 11 was able to inhibit the 
MBNL1–r(CUG)exp complex, we decided to further investigate its DNA-binding properties 
ITC conditions: 
[Ligand]0 = 700 µM 
[Duplex]0 = 10 µM 
[MOPS] = 20 mM 
[NaCl] = 300 mM 
Temperature = 25 ºC 
pH = 7 
Figure 8. ITC profiles of ligand 11 with (a) d(CTG)2 (black) and r(CUG)2 (red). 
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and assess its potential as a possible lead CTG•CAG-binding compound (specifically, the 
d(CAG)exp slipped-strands or d(CTG)exp hairpins structures, and their transcription inhibition 
or length contraction).  
2.3. Investigation of Mode of Binding of Ligand 11 with d(CTG)2 
 Against the other DNA sequences, ligand 11 showed weak and nonspecific binding. These 
preliminary results were encouraging and suggested that ligand 11 is selective of the d(CTG)2 
duplex. To further investigate the mode of binding and whether ligand 11 could be derivatized 
without affecting the binding toward d(CTG)2, methylated derivatives 17 and 22 were prepared 
via a similar synthetic route as ligand 11 (Scheme 2). Their binding affinities were tested using 
ITC with both d(CTG)2 and r(CUG)2 to establish a structure-activity relationship (SAR). 
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Ligands 17 and 22 showed similar binding affinity profile toward d(CTG)2 as ligand 11, 
suggesting that the side from C(1) to N(4) might be involved in the binding, whereas the 
pyrrole nitrogen N(7) is not (Figure 12). Thus, ligand 17 was synthesized from commercially 
available 5-amino-2-methylindole (Scheme 2a), and the synthesis of ligand 22 began with N-
methylation of 5-nitroindole, followed by hydrogenation with Pd/C to obtain the aminoindole, 
and the last two steps were the same as for ligand 11 (Scheme 2b).  
The ITC experiments showed that a large quantity of ligand needed to be titrated into the 
instrument cell to display saturation (i.e., reduction in heat released with each injection). Upon 
the annealing of the two ssDNAs to form a thermodynamically stable duplex structure 
containing one T–T mismatch, one would expect a titration point after 1 molar equivalent of 
ligand is titrated. Surprisingly, the titration curves display a small, but noticeable, “tear-
shaped” drop as the heat released slightly increases from the first to fourth injection, followed 
by less heat released in subsequent injections. These characteristics of the titration isotherm 
appeared to show a cooperative binding mode.84-86 
It is possible to obtain sharper transitions in ITC isotherms by increasing the concentration 
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Table 1. List of oligonucleotide duplexes used in biophysical studies. 
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the critical parameter c, known as the Wiseman 
constant, which determines the shape of the 
binding isotherm. The value c = Kb * n * [DNA]tot 
where Kb is the equilibrium binding constant and 
[DNA]tot is the total concentration of binding 
sites in the cell. ITC experiments are designed to 
have a c value of between 1 and 100 to obtain a 
sigmoidal isotherm allowing accurate 
calculation of K, n, and ∆H values. When c values are >50, the binding isotherms produce 
relatively sharp transitions, whereas experiments with low c values produce much shallower 
transitions and extend to large [L]tot :[DNA]tot (Figure 9).87 Therefore, by varying the DNA 
concentration, a family of related isotherms is obtained. Figure 8 shows a sharper isotherm 
curve as the DNA concentration is increased from 10 µM to 60 µM, each fit with a sequential 
binding of two sites model (provided the lowest 𝜒" value). This model assumes the first ligand 
to bind to the macromolecule at the first site, and the nth ligand to bind goes to the nth site. 
The best fit will generate K, ∆S, and ∆H for each site. This model predicts that the first binding 
event occurs with a KD = 6.4 ± 3 µM, and a second weaker binding event with a KD = 350 ± 
100 µM. ITC experiments with higher DNA concentrations (i.e., 30 and 60 µM) would provide 
better fitting and allow us to obtain fuller saturation in heat of titration, but this would require 
higher amounts of ligand to show saturation. Since the ligand is only soluble in DMSO, this 
means more DMSO will be used which could inhibit the secondary structure of DNA and 
Figure 9. Plot of the effects on the binding isotherm 
of different 𝒄 values. 
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produce excess background heat of dilution throughout the titration experiment. Thus, a more 
water-soluble derivative is needed to saturate the higher DNA concentrations and avoid 
possible issues from DMSO.  
In addition to ITC experiments with ligand 11, analyses using the method of continuous 
variation (i.e., Job plot) and thermal melting curves and were performed to further explore the 
binding mode of ligand 11 with d(CTG)2. In the method of continuous variation, solutions of 
guest and host (e.g., ligand 11 and d(CTG)2, respectively) are combined so that the mole ratio 
of guest:host varies over a wide range while the sum of their concentrations (i.e., total number 
of moles) remains constant. Thus, the maximum amount of d(CTG)2:11 will form when the 
d(CTG)2:11 ratio is the stoichiometric ratio. Ligand 11 and its complex with d(CTG)2 show a  
𝜆%&' at 319 nm and it is also fluorescent. This allowed us to monitor the formation and quantity 
of the d(CTG)2:11 complex via fluorescence spectroscopy (𝜆(' = 319 nm; 𝜆(% = 340–600 nm, 
𝜆(%)*+ = 454 nm). The Job analysis was performed at a total concentration of 60 µM and 
indicated a stoichiometry of 1:1 (ligand to DNA) (Figure 9). When the concentration was 
ITC conditions: 
[Ligand]0 = 700 µM 
[Duplex]0 = 10 - 60 µM 
[MOPS] = 20 mM 
[NaCl] = 300 mM 
Temperature = 25 ºC 
pH = 7 
Figure 10. ITC profiles of ligand 11 with DNA concentrations of 10 µM (black), 30 µM (green), and 60 µM 








increased to 90 µM, a 1:1 ratio was similarly obtained. This study did not agree with the ITC 
experiments because the ITC binding isotherm seemed to show a higher stoichiometry of 
binding. ITC with higher DNA concentration provide a sharper binding isotherm, but, as of 
this writing, we have only been able to use up to 5 and 2.5 molar equivalents of ligand without 
exceeding 7.5% DMSO (Figure 8a). These results suggest the possibility of a single relatively 
high-affinity binding site, followed by a lower-affinity binding site not observed under the 
concentrations used for the Job analysis. Again, we would need a more water-soluble 
derivative of ligand 11 to increase its concentration. 
Mismatch stabilization by ligand 11 was studied through thermal denaturation of the 
resulting complex. Ligand 11 was studied with d(CTG)2 and dsDNA. The results show a 
melting temperature increase of 2.3 ºC when one equivalent of ligand 11 was used with 
 Tm (ºC) ∆Tm (ºC)  Tm (ºC) ∆Tm (ºC) 
d(CTG)2 50.7  DNA duplex 69.84  
+ 1 equiv. ligand 11 52.9 2.3 + 1 equiv. ligand 11 68.52 -1.32 
+ 2 equiv. ligand 11 48.8 -1.9 + 2 equiv. ligand 11 66.1 -3.74 
+ 3 equiv. ligand 11 48.4 -2.3 -- -- -- 
Table 2. Melting temperatures of d(CTG)2 and fully complimentary DNA duplex with different equivalents of 
ligand 11. 
y = 8027786x + 305939 
R² = 0.96 
y = -9571142x + 9772965 
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and d(CTG)2
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𝜆%&' Excitation = 319 nm 







Figure 11. Job analysis of ligand 11 binding to d(CTG)2 at a total concentration of 60 µM. 
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d(CTG)2, and decreases in melting temperature when 2 and 3 equivalents were used (Figure 
10). In contrast, only decreases in melting temperature were observed in thermal denaturation 
experiments of dsDNA and ligand 11 (Table 2). 
2.4. Proposed Water-soluble Ligand 11 Derivatives 
   As noted earlier, methylation at the N(7) and C(8) position did not affect the ITC binding 
isotherm of ligand 11 significantly (Figure 12). Thus, derivatives 28 and 36 were proposed to 
increase the water solubility (Schemes 3 and 4, respectively). The proposed ligand 28 
incorporates a dimethylamino group at the C(8) position to increase the water solubility; this 
group has previously been used in our laboratory to increase the water solubility of some 
ligands. Further derivatization at the N(7) position has been reported to reduce solubility even 
in DMSO.88 Other amines can be incorporated to the acyl chloride intermediate early in the 




































































































synthesis of ligand 28 as well. This could be useful if a dimeric analog were to be developed, 
such as one with two pyrroloquinazoline units linked by a polyamine, or incorporating the 
pyrroloquinazoline unit to another scaffold/backbone. The second proposed ligand 36 shows 
the incorporation of a simple aminomethyl group. The advantage of such derivative would be  
the ability to incorporate a broad range of alkyne-bearing groups to the indole core, but its 
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synthesis involved laborious purifications and was unable to be fully completed. Therefore, 
ligand 28 is a strong lead derivative for future studies and development.  
2.5. Crystallization Efforts of d(CTG)2 –Ligand 11 Complex 
In efforts to obtain a definitive and complete insight into the mode of binding of ligand 11 
and d(CTG)2, we attempted to grow a crystal for solving the structure of the DNA-ligand 
complex. Although we were able to obtain some crystals, unfortunately their quality was not 
suitable for X-ray crystallography. We believe that this could be due to the high percentage 
(5%) of DMSO used in the crystallization efforts, and not enough DNA and ligand in the 
samples ([11] = 1 mM, [d(CTG)2] = 500 µM). Although the biophysical properties of 11 are 
promising, we ultimately need to prepare derivatives with better aqueous solubility not only 
for preparing crystal structures but also for possible future in vitro and in vivo studies. 
2.6. Conclusions and Outlook 
We have identified a new lead d(CTG)-binding compound 11 from a fluorescence 
anisotropy screen performed by Yen-Jun Ho in 2013. Although originally thought to bind 
r(CUG)exp to inhibit the MBNL1–r(CUG)exp complex, ITC binding studies show that it instead 
binds d(CTG)2 with low micromolar affinity and possibly in a cooperative manner. We have 
observed some selectivity toward DNA containing T–T mismatches, but a number of 
confirmatory studies remain to be done. Most importantly, the exact mode of binding of ligand 
11 and its stoichiometry need to be determined, for which the ITC studies contradict the Job 
analysis. For instance, one can use circular dichroism (CD) titration studies to provide more 
insight on how the ligand intercalates within the DNA and the stoichiometry. Ultimately, a 
crystal structure of the d(CTG)2–11 complex is needed to fully understand the mode of binding. 
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Nonetheless, in considering ways in which ligand 11 could bind d(CTG)2 cooperatively, a 
complex that induces base displacement (“flip out”) is possible. Indeed, base flipping in normal 
and mismatched DNA and RNA has been extensively studied and reported,89-93 with small 
molecules such as cyclodextrin and metallointercalators also being able to induce base 
flipping.25,94,95 It is possible that ligand 11 could induce base flipping due to its larger aromatic 
surface area, making it less likely to form a base-triplet while being exposed to the extrahelical 
aqueous environment. Alternatively, two molecules of 11 can bind in one mismatched site, 
though this is unlikely because the Job analysis shows a 1:1 binding stoichiometry. Finally, if 
these studies show promise, ligand 11 is also a potential candidate that could be incorporated 
in the design of fluorescent probes that will help us detect d(CTG)exp. So far, only recently has 




DEVELOPMENT OF ENFORCED-STACKED INTERCALATORS 
3.1. Introduction 
3.1.1. Connecting Ligand 3 Binding Mode to Acridine Ligand Design 
The acridine-based ligand JFA and their analogs that were described in Chapter 1 
possessed excellent binding affinity toward oligonucleotides. However, extensive in vitro 
studies62,73 showed that their cytotoxicity was relatively high; sulforhodamine B (SRB) toxicity 
studies indicated an IC50 = 20.4 ± 0.5 µM for JFA in a 24-hour assay.63,98 In addition, the 
acridine-based ligands exhibited relatively high nonspecific binding toward dsDNA, as 
observed in ITC binding experiments with fully-paired dsDNA.99 
The insights we have gained about the mode of binding of ligand 11 encouraged us to 
continue our efforts to develop acridine-based DNA-selective small molecules. To better 
design these ligands, we took into consideration the possibility that we could influence the 
mode of binding through rational design to favor base flip out. Specifically, designing a ligand 
that potentially favors the induction of a base flip out could result in better binding affinity and 
specificity towards d(CTG)exp. 
3.1.2. Reducing Nonspecific Binding Through Rational Design 
We hypothesized that the cytotoxicity results from the off-target binding of unstacked 
conformers nonspecifically intercalating into the nucleic acids (Figure 13).63 Thus, we believed 
that enforcing the acridine and triaminotriazine units to π-stack would result in a further 
equilibrium shift toward the stacked conformers. To accomplish this, we identified two 
potential strategies oriented toward improving one of our most promising ligands using rational 
design: 1) increasing the π-system area of the recognition unit, and 2) employing a macrocyclic 
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design. Thus, the overall goal of the work in this chapter was to improve the affinity and 
selectivity of our acridine-based ligands.  
3.2. Increasing the π-System Area of the Recognition Unit 
3.2.1. Design and Synthesis of Acridine-Diaminopurine Ligand 
 Accordingly, we set out to search for new aromatic units that would hydrogen-bond with 
thymine and were larger than the triaminotriazine units. In 1988, Lhomme and coworkers 
reported UV/Vis and 1H-NMR studies for a set of acridine-based ligands linked to 
nucleobases.100 The intramolecular ring-ring π-stacking interactions between the acridine and 
adenine or thymine units were found to be very strong in a water/ethanol mixture (95:5 v/v), 
and in particular the acridine-adenine ligands exhibited almost a two-fold degree of stacking 
at room temperature, presumably due to its larger aromatic area.100 It was also observed that 

























Figure 13. Equilibrium between untacked (left) and stacked conformations of ligand JFA. 
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38, R = NH2
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reported a novel set of acridine-based artificial nucleobases that recognized and cleaved DNA 
at apurinic sites (Figure 14).101  
These ligands were also found to exist in the π-stacked conformation at elevated 
temperatures. Ligand 38 was found to bind DNA 5 times stronger than ligand 37 (KD = 0.9 µM 
vs 5 µM), presumably due to 2,6-diaminopurine (DAP) being able to pair with thymine through 
three hydrogen bonds instead of two as with adenine. Thus, we decided to replace the 
triaminotriazine recognition unit with DAP (Figure 15). By conserving the 4-methylene linker 
length, π-stacking between both heteroaromatic units would be heavily favored in water. This 
would allow us to investigate whether a larger aromatic recognition unit, and hence further 
favored π-stacked conformation, decreases the nonspecific binding of our acridine ligands to 
DNA. 
The synthesis of ligand 39 was broadly divided into two parts. The DAP moiety was 
synthesized based on a procedure for ligand 38,101,102 and the water-soluble acridine moiety 
was synthesized based on our previously reported procedure and introduced at the final 
stage.103 As described in Scheme 5, the key diaminopurine intermediate 42 was prepared from 
DAP following the method reported by Leonard for the alkylation of adenine.104 Introduction 
of the aminoalkyl chain was achieved by alkylation of the purine with 4-
bromobutylphthalimide in DMF the presence of sodium hydride. The reaction took place 
regioselectively at position 9 (44% yield); no alkylation at the N(7) position was observed.  































Deprotection of the amine was achieved in 85% yield by hydrolysis of the phthalimide group 
in acidic conditions (HCl/AcOH/H2O). The purification of intermediate 42 turned out to be a 
major challenge due to its high polarity. Although we attempted a number of purification 
methods, ultimately, we had to perform an extraction from water (pH 12) and 10:1 (v/v) 
chloroform:isopropanol and subsequently use flash column chromatography. The acridine 
intercalating moiety 44 was prepared via an Ullmann-type coupling of anthranilic acid and 2-
chlorobenzoic acid,105 followed by oxidation with thionyl chloride to afford the chloroacridine 
43, and then amidation of the acyl chloride with N,N′-dimethylethylenediamine in an overall 
yield of 53%. Finally, the coupling of 42 and 44 was performed in DCM with DIPEA at 65 ºC 
as previously described64 to afford 39 in 54% yield. Using similar conditions,  the 











    RT, 24 h
2.



























































alkyltriaminotriazine 4662 and acridine 44 were coupled to  produce control ligand 47 (Scheme 
6).  
3.2.2. Biophysical Studies of DAP-Acridine Ligand 
To quantitatively determine the affinity and selectivity of ligand 39, isothermal titration 
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Table 3. List of oligonucleotide duplexes used in biophysical studies. 
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various DNA and RNA 10-mer targets: r(CUG)2, d(CTG)2, d(CAG)2, and d(CCG)2 (Table 3 
and Figure 16). The resulting data were fit to a two-site sequential binding site model, with the 
second binding KD (200–400 µM) attributed to nonspecific binding.62 Ligand 39 was found to 
bind to d(CTG)2 with low micromolar affinity (KD = 8.9 ± 0.6 µM), but exhibited very weak 
binding interactions with r(CUG)2 and nonspecific binding (likely nonspecific intercalation) 
to d(CAG)2 (Figure 16). In addition, the absorption spectrum of 39 was measured at 20 µM 


































































































































































Figure 16. ITC binding isotherms of 39 to r(CUG)2 (a), d(CTG)2 (b), d(CCG)2 (c), and d(CAG)2 (d). 
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with d(CTG)2. It exhibited a 30% decrease in the 
absorption and a redshift of 10 nm, indicative of 
intercalation of the ligand into the DNA (Figure 
17).106 However, further ITC experiments revealed 
a low micromolar affinity (KD ~ 3 µM) to d(CCG)2 
(Figure 16c). Although not expected, it was not a 
complete surprise as the DAP unit can form two 
hydrogen bonds with cytosine. The similarly 
strong binding of 39 to d(CCG)2 could suggest that 
it is selective for pyrimidine mismatches in DNA. 
However, the C–C mismatch is one of the least stable mismatch pairs in DNA and very weakly 
hydrogen-bonded.107 In fact, it has been reported that it can become unstacked from the DNA 
helix and adopt extrahelical locations.108 Thus, the weakly mismatched C–C basepairs could 
facilitate the extrahelical displacement (“flipping”) of a mismatched cytosine by the DAP 
while it π-stacks within the DNA duplex and hydrogen-bonds with the other cytosine (see 
below and Section 3.2.3). 
The ITC isotherms did not show a clear curve inflection point to visualize a binding 
stoichiometry of the ligand-DNA complex. Thus, using the inherent fluorescence of the 
acridine moiety of 39, a Job analysis was carried out at a total concentration of 40 µM, 
indicating a 1:2 d(CTG)2:39 binding stoichiometry (Figure 6a). A similar Job plot was obtained 
when 39 was examined with d(CCG)2. When a Job analysis is performed a lower total 
concentration of 10 µM, a 1.2:1 stoichiometry was observed. These results suggest that a 




















Ligand 3 0.1:1 DNA:Ligand
0.5:1 DNA:Ligand 1:1 DNA:Ligand
2:1 DNA:Ligand
Figure 17. UV-Vis absorption spectrum of 39 and 
sequence d(CTG)2 at different molar ratios. 
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constant obtained from the ITC experiments (KD(2)) was originally thought to be associated to 
nonspecific interactions to the DNA,109 this binding constant is likely to be from the second 
binding interaction at the mismatch. These observations add evidence that the DAP unit of 
ligand 39 potentially induces a base flipping in DNA, but the binding stoichiometry observed 
of 2:1 needs to be considered. (see Section 3.2.3). 
Finally, to assess whether the larger recognition unit had an effect on the ligand’s 
nonspecific binding, ITC experiments were performed using dsDNA and ligand 39 and control 
47 (Figure 7). Unfortunately, a similar titration isotherm was obtained for both ligands, 
Figure 18. (a) Job plot analysis of 39 with oligonucleotide sequence C (left) and E (right) at a total concentration 
of 40 µM. The left and right lines in each graph were fitted with a linear model using the first 5 and last 3 data 
points, respectively. Job analyses were duplicated and were within ± 15%. (b) Cartoon representation of a potential 
mode of binding with 2 molecules of ligand 39 and one mismatched DNA site (X = T or C) based on Job analysis. 
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suggesting that the larger aromatic recognition unit does not enforce the intramolecular π-
stacking enough to prevent nonspecific intercalation of the ligand to DNA. 
3.2.3. Conclusions and Outlook 
A new stacked intercalator ligand has been developed with a larger heteroaromatic 
recognition unit. Low micromolar affinities were in a 2:1 binding stoichiometry were observed 
for ligand 39 and d(CTG)2. In addition, ligand 39 showed the same stoichiometry and moderate 
binding affinity for d(CCG)2. Negligible binding was observed with duplex strands containing 
U–U, A–A, or G–G mismatches. Although not entirely selective of T–T mismatches, the 2,6-
diaminopurine unit can be incorporated into future ligands to target C–C mismatches, in 
addition to single base bulges (C or T). The nonspecific binding of 39 and 47 toward a 10-mer 
duplex DNA was assessed and compared through ITC studies. Both DAP ligand 39 and control 
47 exhibited similar isotherm profiles, suggesting the larger 2,6-diaminopurine recognition 
unit did not reduce the nonspecific intercalation of the ligand throughout the DNA duplex. 
Figure 19. ITC binding isotherms of ligands 41 (a) and 44 (b) to sequence A. 
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Further studies to need to be conducted to study if ligand 39 induces a base flip out at low 
concentrations. For instance, regarding the T–T mismatch, oxidation of the C(5)-C(6) double 
bond of the T base with potassium permanganate would be more feasible for the T base in the 
extrahelical position compared to that in the intrahelical position of the duplex.110 Some models 
of preliminary modes of binding can be envisioned, such as one ligand binding to one 
mismatched nucleobase and produce a pseudo bulge that allows the binding of another ligand 
from the opposite direction (Figure 18b), similar to a proposed zigzag intercalation of two 
naphthyridine rings by Nakatani.111Although this mode of intercalation would violate the 
nearest neighbor exclusion principle,13 it should not be excluded. Obtaining a crystal structure 
would provide conclusive information on the mode of binding. 
3.3. Employing a Macrocyclic Design 
Although the intramolecular ring-ring π-stacking interactions in acridine-purine ligands 
had been reported to be very strong and exhibit an almost two-fold degree in stacking over 
acridine-adenine,100 we did not observe a reduction of nonspecific binding toward DNA (vide 
supra). Next, to further improve the affinity and selectivity of our acridine-based ligands, we 
proceeded to develop enforced stacked intercalators through our second strategy: a 
macrocyclic design. 
3.3.1. Macrocyclic Bisintercalators 
Macrocyclic bisintercalators, also known as cyclobisintercalators, are a unique class of 
DNA ligands, and one of the most extensively studied macrocycles belonging to the class of 
heterophanes112 and cyclophanes.113 In the late 1980s, Lehn developed macrocyclic 
bisintercalators consisting  of homo- or heterodimeric heteroaromatic units (e.g., acridine, 
naphthalene, phenanthridine, phenazine, anthracene, imidazolium, bipyridine and/or biphenyl) 
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connected by two relatively short flexible linkers, and can adopt a semi-closed, 
intramolecularly π-stacked conformation in the free state.7 These molecules were initially 
shown to bind metal ions114 and, due to their topology, were also able to “sandwich” (i.e., 
encapsulate) other flat aromatic guests through intercalative supramolecular structures.115 
 In recent decades, several cyclobisintercaland derivatives have been effectively utilized 
for host-guest and undergo selective with various biomolecules (e.g., nucleotides, proteins, 
amino acids).19,116 Zimmerman reported in 1989 the first macrocyclic bisintercalator 48 able 
to bind a DNA duplex (Figure 20a),117,118 but it was not until 2003 that Teulade-Fichou reported 
49,30 the first of this type to recognize mismatch sites and induce base-displacement 
(“flipping”) in DNA (Figure 20b). The two heteroaromatic units of the macrocyclic 
bisintercalator sandwich a neighboring base pair, with one unit being inserted in an abasic 
site119 or flipping a mismatched base pair out of the DNA helix30  A series of derivatives were 
developed to investigate their mismatch-binding properties, showing good selectivity for T–T 
and T-C mismatches (though not between these mismatches).31 More recently, Nakatani has 

































developed a series of macrocyclic bisnaphthyridine dimers 50 that bind DNA bulges120 and 
mismatches (Figure 20c).121 
3.3.2. Macrocyclic Ligand Rational Design 
The design of the macrocyclic ligands required the following: 1) an appropriate handle for 
the attachment of the additional linker, and 2) suitable linker lengths to enforce π-stacking 
between the two aromatic heterocycles while allowing adjustment to the binding site. As 
mentioned earlier, our lab had designed ligand JFA with an acridine intercalating unit to 
provide the hydrophobic driving force for binding and a triaminotriazine unit as a Janus-wedge 
to form a base triplet with U–U or T–T mismatches.62,73 The carbon linker between the acridine 
and triaminotriazine units was important in offering the conformational flexibility needed for 
the concurrent binding of these two units to the target mismatch. Although the two heterocycles 
are believed to π-stack, there still exists an equilibrium between the stacked and unstacked 
conformers (Figure 13). Thus, to structurally enforce the π-stacking of the acridine and 
triaminotriazine units, an additional carbon linker was introduced between the two 
heterocycles (Figure 21).  
The introduction of an additional linker required modifying the acridine with a reactive 
functional group and the triaminotriazine recognition unit without affecting its hydrogen-


























Figure 21. Structural progression from acridine-based ligands to macrocyclic bisintercalators. 
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opposite sides of the acridine unit to favor π-stacking with the triaminotriazine unit as much as 
possible. We had previously reported more water-soluble derivatives of ligand JFA by using 
a different intercalator, N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), which 
gave the option to use a carboxylic acid group at the 4-position that could be amidated with an 
amine linker.65,103 It had been previously reported that placing a carboxylic acid group in the 
3-position is synthetically challenging because it produces an inseparable mixture with the 
isomer at the 1-position.122 In addition, using the methyl scanning method we had showed that 
the amino groups on the triaminotriazine unit of JFA could bear an alkyl substituent without 
Figure 22. Energy-minimized complex modeling showing ligand A4D3 binding to a mismatched CTG site. The 
triaminotriazine unit of the ligand hydrogen-bonds to one of the mismatched thymines. (T = magenta, C = teal, G = 
light green.) Computational modeling performed by Lauren Hagler. 
 38 
affecting its binding toward d(CTG)2.73 Therefore, we decided to introduce the additional 
linker connected at one of the triaminotriazine amines and at the 4-position of the acridine unit.  
Whereas most macrocyclic bisintercalators recognize nucleic bases and mismatched sites 
by stacking between two separate base pairs, the macrocycles in this work were designed with 
short linkers to form a macrocycle small enough so that intercalation is only possible between 
the GC base pair and the mismatched base pair site and the triaminotriazine unit either forms 
a base triplet or cause a base flip out. In order to assess the length of the linkers and π-stacking 
between the acridine and triaminotriazine units, Lauren Hagler, a graduate student in the 
Zimmerman Group, performed molecular modeling computations. The macrocyclic 
conformation in the presence of water was modeled in the computational modeling program 
Molecular Operational Environment (MOE). The DNA sequence synthesizer in MOE was 
used to create the DNA duplex containing CTG mismatched sites. A model macrocycle with 
3- and 4-methylene linkers (A4D3) to provide enough conformational flexibility was built and 
energy-minimized using the build function of the software. A final energy minimization of the 
entire A4D3–DNA complex produced the structure in Figure 22. This energy minimized 
structure of the ligand shows its enforced stacked conformation, where the triaminotriazine 
and acridine units are π-stacked. As can be seen, one side of the recognition unit of the ligand 
interacts with one of the mismatched T-bases (shown in magenta), while the other T-base is 
pushed out into an almost a flipped-out position. This helped us choose linkers that would 
provide enough flexibility to allow the triaminotriazine unit to adjust and bind at the 
mismatched bases. Likewise, A4D3 was modeled with a crystal structure for an RNA sequence 
containing CUG mismatched sites (PDB ID: 3gm7), and no low-energy minima was observed, 
suggesting no global minima and possibly no binding of A4D3 to the RNA. 
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3.3.3. Synthesis of the Macrocyclic Ligands 
 A series of five cyclobisintercalators were synthesized with different linker lengths, 
ranging from five to eight atoms (Scheme 7).  The goal of this small library was to determine 
the optimal linker lengths separating the two heteroaromatic units, and to study whether the 
extra flexibility affects binding selectivity to mismatched bases. The synthesis of the ligands 
was divided in two parts: synthesizing the recognition moiety with both linkers attached, 
followed by coupling to the acridine intercalating unit. Attaching the linkers to the acridine 
unit first was also considered, but due to the slow hydrolysis of 9-aminoacridines at the N-9 
position, it was best to limit the number of steps performed with this unit in place. By 
controlling the temperature, 2,4,6-trisubstituted triazines can be prepared by sequential 
selective addition of nucleophiles (e.g., amines).123 Thus, triazine 51 was prepared by treating 
2,4,6-trichloro-1,3,5-triazine124 with ammonia and water at 0 ºC. Addition of the appropriate 
mono Boc-protected diamine at room temperature afforded triazine 52. Finally, addition of a 
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solution of 52 to a large excess of the appropriate diamine afforded the triazine recognition 
moiety 53. Its purification, and in particular the removal of the excess diamine, was challenging 
and ultimately, silica flash chromatography was used with DCM:MeOH:NH4OH (10:1:0.1 v/v) 
as the eluent. The free amine was reacted with the acyl chloride group in acridine 43 to produce 
intermediate 54. After purification and removal of most impurities, intermediate 54 was briefly 
treated with TFA to remove the Boc group. Finally, intramolecular cyclization was performed 
under very dilute conditions (~1 mM), affording the corresponding macrocycles in fair yields. 
The cyclization conditions were especially challenging, as solvents and reagents needed to be 
extremely anhydrous due to the potential of any water interfering with the reaction at the 9- 
chloro position of the acridine. Using similar conditions and previously reported conditions62, 
the noncyclic control ligand 56 was prepared (Scheme 8).  
3.3.4. Biophysical Studies of the Macrocyclic Ligands 
 The binding affinity and selectivity for T–T, U–U, A–A, G–G, C–C mismatches, and 
dsDNA were studied using ITC. The macrocycles were titrated into solutions of various 
DNA/RNA 10-mer duplexes containing a single mismatched CXG site (X = A, T, C, G, or U) 
were used (Table 4). The binding isotherm data was fit to a one-site binding model. All the 
macrocycles showed similar binding affinity to d(CTG)2 (KD = 19–35 µM) and apparent 
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stoichiometries of 1:1, whereas none of the macrocycles showed detectable binding toward U–
U, G–G, and A–A mismatches (Table 5). Control ligand 56 bound moderately to U–U 
mismatches, slightly weaker than the reported value for JFA (~2 µM, although this was 
calculated using a two-site sequential model). We were particularly interested in the 
nonspecific binding toward duplex DNA of the macrocycles versus the noncyclic analog 56. 
Control ligand 56 bound dsDNA nonspecifically with an affinity of 69 ± 25 µM. On the other 
hand, none of the macrocycles showed detectable binding affinities toward duplex DNA 
(Figure 11). Due to the instrument’s upper detection limit, it is estimated that the binding is >1 
mM. 
Table 4. Oligonucleotide duplexes used for biophysical studies. The structures shown represent the most stable 
structures predicted by m-fold. 
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In addition, only three macrocycles, A3D4, A4D4, and A5D5, showed weak binding 
toward C–C mismatches (sequence E; 404 µM, 155 µM, and 125 µM respectively), similarly 
to control 56 (159 ± 22 µM) and about 20-80 times weaker than JFA (5.0 ± 0.2 µM).62 As 
observed for acridine-DAP ligand 3, because the C–C mismatch is very unstable,107 the 
macrocycles A3D4 and A4D4 could be displacing a mismatched cytosine into an extrahelical 
position. Overall, although the T–T mismatch binding-affinity was slightly reduced, these 
results show that the nonspecific binding toward dsDNA was greatly reduced with a 
macrocyclic structure. 
To further analyze and quantify the reduction in nonspecific binding between the 
macrocycles and control 56 toward dsDNA, reverse binding titrations were performed using 
fluorescence spectroscopy. The fluorescence change due to binding was monitored as 1-µL 
aliquots of DNA at various concentrations were manually titrated into solutions of [A4D3]0 = 
0.2 µM, and the data was fit to a one-site binding model using the software Prism. A clear 
decrease was observed when the d(CTG)2 was titrated into solutions of A4D3 and 56, with KD 
values of 0.8 ± 0.6 µM and 3.5 ± 2 µM, respectively. The binding affinities of the control 
Table 5. Equilibrium dissociation constants* (apparent KD, µM) of A3D3, A3D4, A4D3, A4D4, and A4D5 to 
various oligonucleotides determined by ITC. 
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ligand is comparable to that obtained from ITC; however, the binding affinity for A4D3 is 
about 20-fold lower. The reason for this inconsistency is not known at this time. 
Furthermore, when titrating solutions of dsDNA into the ligands’ solutions, the data 
obtained was irregular from trial to trial. Given the uncertainty and error involved, no fit could 
be confidently used to assess the strength of binding of the macrocycles to dsDNA. As an 
alternative attempt to quantify the difference in nonspecific binding between the macrocycles 
and the noncyclic control ligand toward dsDNA, ethidium displacement experiments were 
performed. When macrocycle A3D3 was titrated to duplex A complexed with ethidium, 
minimal ethidium displacement occurred. However, when the control ligand 56 was titrated to 
Figure 23. ITC binding isotherms of A4D3 (a) and 56 (b) to sequence A. The binding isotherm for A4D3 is 
representative of the other macrocycles and sequence A (see Appendix). 
56 25 ºC 
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a ethidium:A complex, ethidium was readily displaced (Figure 25). Fitting the data to a one-
site model provides an apparent KD of 1.6 ± 0.5 and 5.8 ± 2 µM for the control and macrocycle, 
respectively, suggesting the macrocycle can displace ethidium 4 times less than the noncyclic 
control ligand. This result indicates and confirms the weaker nonspecific binding of A3D3 
relative to the noncyclic control A similar result was obtained from a single trial displacement 
experiment with A4D3.  
Scheme 9. Synthesis of control NC2. 
Figure 24. Ethidium displacement experiment in which A3D3 (red) and 56 (blue) are titrated to ethidium:dsDNA 
complex, showing the noncyclic control was able to displace ethidium about 4 times more than the macrocycle 
















As all the macrocycles had comparatively moderate binding affinities and similar 
stoichiometries by ITC, we chose A4D3 as a model ligand and starting point to study the mode 
of binding toward DNA. Evidence of an intercalative binding with a 1:1 A4D3:DNA ratio was 
obtained in a few ways. First, a Job plot analysis at a total concentration of 50 µM using 
sequence C gave a maximum concentration of complex with a ligand mole fraction of 0.49, 
which indicates a 1:1 stoichiometry (Figure 24a) and validates one high-affinity binding site 
observed in ITC. Also, UV/Vis titration experiments showed a red shift of 5 nm of the visible 
absorption band of the macrocycle as the DNA:A4D3 ratio increased from 0.1 to 2, suggesting 
Figure 25. (a) Job analysis of ligand A4D3 to d(CTG)2 duplex A at a total concentration of 50 µM. The left and 
right lines in each graph were fitted with a linear model using the first 4 and last 4 data points, respectively, 
intersecting at a ligand mole fraction of 0.49, indicating a 1:1 stoichiometry. Error bars represent standard 
deviation of three independent experiments. (b) Absorption spectrum of A4D3 with duplex C at various ratios. 
The bottom spectrum is a zoomed-in window from 350 nm–500 nm. 
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the ligand was intercalating in the DNA (Figure 24b). (All other macrocycles in the presence 
Figure 26. 1H NMR spectra of A4D3 (green, top) and NC2 (red, bottom) in D2O at ca. 200 µM. The observed 
upfield chemical shifts of A4D3 indicate intramolecular π-stacking in water. 
Figure 27. (a) Job analysis of A4D3 with d(CTG)4 duplex G at a total concentration of 60 µM (blue) and 200 µM 
(red) indicating a 1.5 : 1 and 1.9 : 1 stoichiometry, respectively. (b) Job analysis of A4D3 with d(CTG)6 duplex H at 
60 µM (right) indicating a 2.1 : 1 stoichiometry. The left and right lines in each graph were fitted with a linear model 
using the first 4 and last 4 data points, respectively. Job analyses were duplicated and were within ± 15%. 
(a) (b) 
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of d(CTG)2 exhibited similar spectra.)  
Sequences G and H, containing 2 and 3 CTG sites, respectively, were chosen to examine 
the ability of A4D3 to bind multiple sites within a CTG repeat structure. Job analyses at a total 
concentration of 60 µM to study the binding stoichiometry of A4D3 to DNA duplexes G and 
H resulted in binding ratios of 1.5:1 and 2:1 A4D3:DNA, respectively (Figure 25a and 25b). It 
is worthwhile to note that these results are consistent to the reported stoichiometries observed 
with JFA.62 The proximity in binding sites limits the complexation of two ligands in sequence 
G. In sequence H, a 2:1 stoichiometry is observed, presumably from two ligands binding at the 
terminal CTG sites and leaving the central CTG site empty. Indeed, when a Job analysis was 
performed with A4D3 and sequence G at a higher total concentration of 200 µM, the binding 
stoichiometry observed was 1.9:1 (Figure 25a, red). Overall, it appears that the enforced 
stacking prevents the macrocycles from intercalating nonspecifically because it is not possible 
for the two adjacent base pairs to separate by the thickness of the two stacked aromatic 
heterocycles (6.8 Å)12 except at sites containing a mismatch. All five macrocycles appear to 
bind to CTG sites with a similar affinity, suggesting the change in freedom of the recognition 
unit by varying linker lengths does not significantly affect the binding affinity.  
Lastly, the intramolecular π-stacking of A4D3 was studied by 1H NMR in deuterium oxide 
at low concentrations (ca. 200 µM). As a control ligand, acridine NC2 was synthesized 
relatively straightforward (Scheme 4). The acridine protons showed an upfield signal shift for 
A4D3 due to shielding, compared to the chemical shift of the acridine protons in NC2. This 
observation indicated intramolecular π-stacking between the two aromatic units in aqueous 
solution (Figure 26). 
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3.3.5. Cytotoxicity and Transcription Inhibition Assays with Lead Macrocyclic Ligands 
As mentioned earlier, we hypothesized that the cytotoxicity of our acridine-
triaminotriazine ligands results from the off-target binding of unstacked conformers 
nonspecifically intercalating into the nucleic acids (Figure 1). Thus, we wanted to study the 
effect of a macrocyclic structure on cell viability. The following cell uptake, cytotoxicity and 
transcription inhibition assays were carried out by JuYeon Lee, a graduate student in the 
Zimmerman Group. Live HeLa cells were incubated with 30 µM of A4D3 for 12 hours. 
Confocal microscopy images provided preliminary semiqualitative evidence that the 
macrocyclic ligand could pass through the cell membrane and enter the nucleus (Figure 27). 
Next, to assess in vitro cytotoxicity, sulforhodamine B (SRB) colorimetric assays, an 
effective and one of the most widely used methods were performed using HeLa cells.125,126 
SRB is a bright-pink aminoxanthene dye known to bind protein components of cells. The 
amount of SRB bound to proteins is directly proportional to total protein content, thus 
providing information about total cell mass (i.e., growth). HeLa cells were treated with serial 
concentrations of 100 µM to 0.2 µM of the five macrocyclic ligands and control 56. After 
being incubated at 37 oC for 72 h, the cells were fixed and treated with SRB. The bound SRB 
Figure 28. Cellular uptake of ligand A4D3 into HeLa cells monitored by confocal microscopy. Images of live cells 
were taken after incubating for 12 h with a ligand concentration of 30 µM. The acridine units of the macrocyclic 
ligand showed inherent fluorescence (left). 
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was extracted and its fluorescence was measured. The percentage of cell death was calculated 
by comparing with untreated samples, and it was plotted against concentrations of the 
macrocycles. The IC50 values, which is the concentration resulting in 50% cell death, ranged 
from 100 – 12 µM (Figure 28). The control ligand 56 showed a similar IC50 value to our initial 
acridine ligand JFA (~20 µM after 24 h).98 In addition, no observable cell death was found for 
ligands A3D3 and A3D4 in this cell line at concentrations as high as 25 µM for 72 h. However, 
significant cytotoxicity was observed for A4D4, A4D3, and A5D4 at this concentration (Figure 
28). This suggests that the cytotoxicity of the acridine-based ligands does not necessarily 
depend on macrocyclic or noncyclic structure. The only two macrocycles that showed a lower 
toxicity profile than 56 were A3D3 and A3D4. Ligands A4D4 and A4D3, which contain the 
same linker length between the acridine and triaminotriazine units as JFA, showed a very 
similar toxicity profile to control 56. 
These results do not support our hypothesis that the cytotoxicity observed in our noncyclic 
acridine-based ligands is due to their nonspecific intercalation into the nucleic acids. Although 
the reason for the macrocycles’ toxicity is currently not known, there appears to be a trend in 
the linker lengths. Ligands A3D4 and A3D3 with 3-methylene linkers off of the 9-position on 
the acridine unit exhibit the lowest cytotoxicity. However, A4D3, A4D4, and A5D5 with 4-
methylene and 5-methylene linkers at the same position exhibit ~5-fold higher cytotoxicity, 
which is similar to that observed by the noncyclic control 56. One could argue that the larger 
size of the molecules, and thus their overall hydrophobicity, has an effect as those with longer 
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linker lengths exhibit higher toxicity. However, macrocyclic ligands A3D4 and A4D3 show 
every different IC50 values (~100 and ~20 µM, respectively).  
Although preliminary molecular modeling does not show a clear difference in the way 
A3D4 and A4D3 interact with d(CTG)2, as they both appear to π-stack and hydrogen-bond 
similarly to the mismatched site, our results suggest that the shorter A-linker (i.e., A3D3 and 
A3D4) could be affecting the ligands’ conformations and toxicity. Further computational and 
biological studies need to be conducted to investigate the nature of our noncyclic ligands. One 
possibility is that the noncyclic ligands do not intercalate nonspecifically to a significant extent 
Figure 29. Evaluation of the toxicity of the macrocycles to HeLa cells. The ligands were incubated with cells 
for 72 h and the cell death was assessed using sulforhodamine B (SRB). Error bars represent standard deviations 
of three independent experiments. 
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with dsDNA to cause toxicity at the studied concentrations, but instead interact and interfere 
with processes in cells that lead to cell death. For example, the macrocycles could be 
interacting with single-stranded DNA or interfering with proteins involved in DNA repair 
processes, eventually triggering cell death. 
Next, due to the ability of the macrocyclic ligands to selectively bind T–T mismatches, we 
wanted to assess their potential for (CTG•CAG) transcription inhibition. The in vitro 
transcription inhibition assay used linearized CTG74 plasmid and a T7 promoter located in the 
upstream region of the repeats. Macrocycles A3D3, A3D4, and A4D3 were selected based on 
their binding affinities toward CTG sites and their cytotoxicity profiles. Macrocycles A3D3, 
Figure 30. Plot of the percentage of in vitro transcription of CTG74 versus ligand concentrations. Ligands at 
different concentrations were incubated with 15 ng of linearized CTG74 in a T7 RNA polymerase mixture. 
After 1.5 h, the reaction mixture was loaded on a 10% denaturing gel. Noncyclic control 56 is NC. 
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A3D4, and A4D3 moderately inhibited the production of r(CUG)exp (~60–80% at 25 µM) in a 
dose-dependent manner, whereas the noncyclic control ligand 56 showed ~45% inhibition 
(Figure 29a, NC). In addition, to study the selectivity and potentially the target of the 
inhibition, similar experiments were performed with a control plasmid that lacked repeats. 
Ligand A4D3 showed <10% transcription inhibition at 0–50 µM (<20% at 100 µM), whereas 
A3D3 showed ~45% inhibition at 100 µM and A3D4 showed ~45% inhibition at 50 µM. In 
contrast, the control ligand 56 showed ~45% inhibition at 50 µM (Figure 29b). Interestingly, 
the most effective inhibitor, A4D3, was the most selective inhibitor yet also a relatively toxic 
macrocycle. It is important to point out that the macrocycles were still able to inhibit 
transcription using dsDNA that did not contain mismatched base pairs, which suggests, given 
their minimal binding affinity toward dsDNA, that the macrocycles likely inhibit transcription 
through ways other than binding the d(CTG)exp hairpin that is proposed to exist during 
transcription.33,34,42 Taking all the results into account, macrocycle A3D3 appears to be the 
overall better macrocycle due to its lower cytotoxicity; however, there does not seem to be a 
clear trend between structure and bioactivity. It is possible that the macrocycles could perform 
differently in vivo, and the results thus far do not reflect the complexity environment of the 
cell. 
3.3.6. Conclusions and Outlook 
Through rational design, we have developed a new class of water-soluble 
cyclobisintercalators that selectively target T–T mismatches and have negligible nonspecific 
binding toward dsDNA. They are able to penetrate through the cell membrane, are less 
cytotoxic, and about twice as efficient at inhibiting the transcription of d(CTG)exp to r(CUG)exp 
than the noncyclic analog, 56. More significant was the unexpected discovery that the 
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macrocyclic structure design of our ligands did not necessarily correlate with a reduction in 
their cytotoxicity in HeLa cells. Whereas ligands A3D3 and A3D4 showed almost 10-fold 
lower toxicities compared to noncyclic control 56, A4D4 and A4D3 showed a very similar 
toxicity profile (Figure 28). The contrasting cytotoxic profiles of A3D4 and A4D3 (IC50 >100 
and ~20 µM, respectively) suggest that molecule size does not have a significant effect on 
toxicity, but rather the molecular conformations play a significant role. In addition, varying the 
lengths of the linkers in the macrocyclic ligands did not have a significant effect on their 
binding affinities toward CTG sites.  
A few key questions still remain: 1) What is the nature of the cytotoxicity of the acridine-
based ligands (cyclic and noncyclic)? 2) What is the mode of binding of the macrocyclic 
ligands to DNA? To further investigate the cytotoxicity of the acridine-based, one could take 
advantage of activity-based protein profiling methods, specifically tandem-orthogonal 
proteolysis (TOP)-activity-based protein profiling (ABPP),127 to explore potential protein 
targets that could be triggering cell death. Regarding the macrocyclic ligands presented here, 
one could modify the synthesis to include an alkyne group that would allow the protein-
macrocycle complex to be pulled down and be analyzed using mass spectrometry. 
Lastly, due to the very weak binding observed of A3D4, A4D4, and A5D5 toward C–C 
mismatches, it is possible that the macrocycles induce a base flip out as the C–C mismatches 
are one of the least stable base pair mismatches.108 In efforts to increase the binding affinity of 
the macrocyclic ligands, it may be possible to utilize a different recognition unit that positioned 
more favorably to hydrogen-bond with a T-base. For example, one could use a 
triaminopyrimidine unit instead of the triaminotriazine unit to possibly position the 
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donors/acceptors more favorably. Alternatively, a different intercalating unit could be used to 
enhance the intrahelical π-stacking of the ligand in the mismatched site. 
These findings will aid our design and optimization efforts of future mismatch-targeting 
ligands, and we are particularly interested in better understanding their cytotoxicity mode of 
action. Although the macrocycles in this work showed slightly better transcription inhibition 
of d(CTG)74 than the noncyclic control ligand, further optimization of the design could enhance 





MATERIALS AND METHODS 
4.1. General Methods 
Unless otherwise stated, all solvents and reagents were of reagent quality, purchased 
commercially, and used without further purification. Water was purified by a Millipore Direct 
Q-5 purification system. DNA and RNA oligomers were purified by standard desalting and 
obtained from Integrated DNA Technologies. All chemical reactions were performed under 
nitrogen unless otherwise specified. Abbreviations used: Boc (tert-butyloxycarbonyl), Cbz 
(carboxybenzyl), DCM (dichloromethane), DIPEA (diisopropylethylamine), DME (1,2-
dimethoxyethane), DMF (dimethylformamide), TEA (triethylamine). 
High- and low-resolution resolution mass spectra were obtained by the Mass Spectrometry 
Laboratory, School of Chemical Science, University of Illinois. Mass spectra were obtained 
by ESI on a Waters Micromass Q-Tof. High-performance liquid chromatography (HPLC) was 
performed by a Dynamax SD-200 system with a UV detector set at 254 nm using an Alltech 
Denali C-18 column (250 x 10 mm) with a dual solvent system of (0.1:100 v/v) TFA/H2O 
(Solvent A) and (0.1:100 v/v) TFA/MeOH (Solvent B). Nuclear magnetic resonance (NMR) 
spectra were recorded on a Varian Unity 400, Varian Unity 500 or Varian INOVA 500NB 
spectrometer at ambient temperature (22 ± 3 °C) unless otherwise mentioned. Chemical shifts 
(δ) are reported in parts per million (ppm). Coupling constants (J) were reported in Hertz. 1H 
NMR chemical shifts were referenced to the residual solvent peak at 7.26 ppm in chloroform-
d (CDCl3) and at 2.50 ppm in DMSO-d6. 13C NMR chemical shifts were referenced to the 
center solvent peak at 77.16 ppm for CDCl3 and at 40.45 ppm for DMSO-d6. Unless otherwise 
stated, analytical thin-layer chromatography (TLC) was performed on Merck pre-coated silica 
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gel 60 F254 plates. Flash column chromatography was performed on 40-63 µm silica gel (SiO2) 
mixed with Fluorescence Indicator green 254 nm in quartz columns to allow monitoring of 
fractions with a UV lamp. Unless otherwise stated, all purification columns were slurry-packed 
and wet-loaded with the crude mixture. Solvent mixtures used for chromatography are reported 
as volume ratio (v:v). The purity of all ligands was estimated to be >99% by 1H NMR and by 
HPLC. Stock DNA and RNA solutions were prepared using biological grade water and THE 
Ambion® RNA Storage Solution (Life Technologies), respectively, and the concentrations 
were determined by performing absorbance measurements at 25 °C on a Shimadzu UV-
2501PC spectrophotometer (Kyoto, Japan). The concentration of each single-stranded 
DNA/RNA was calculated using Beer’s law with the extinction coefficient (ε260) provided by 
the supplier. 
Isothermal Titration Calorimetry. Isothermal titration calorimetry (ITC) measurements 
were performed at 25 °C on a MicroCal VP-ITC (MicroCal, Inc., Northampton, MA). A 
standard experiment consisted of titrating 10 µL of a 500 or 700 µM ligand from a 250-µL 
syringe (rotating at 300 rpm) into a sample cell containing 1.42 mL of a 10 µM DNA or RNA 
solution. ITC experiments consisted of 28 total injections (first injection was 1–5 µL over 5 s, 
subsequent injections were 10 µL over 20 s), with a delay of 400 s between injections. The 
initial delay prior to the first injection was 300 s. To derive the heat associated with each 
injection, the area under each isotherm (microcalories per second versus seconds) was 
determined by integration by the graphing program Origin 7.0 (MicroCal, Inc. Northampton, 
MA). The first data point from each ITC experiment was omitted when fitting to binding 
models due to possible diffusive mixing of material near the tip of the syringe.128 The fitting 
requirements were such that the thermodynamic parameters were derived from curves that 
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produced the lowest amount of deviation. In most cases, fitting to a sequential site binding 
model of two binding sites gave the most accurate data, and in some cases a two-site binding 
model fit best. The ligand stock solution was 10 mM in biological grade water. Double-
stranded and hairpin DNA or RNA solutions were freshly prepared by mixing required 
volumes of the corresponding single stranded oligomers and annealing by heating in a water 
bath at >90 °C for 5 min and slowly cooling to room temperature over 60-90 min. MOPS buffer 
solution (1 M, pH 7 ± 0.2), NaCl solution (5 M), and biological grade water were added to 
make up an oligonucleotide solution with 20 mM MOPS and 300 mM NaCl. For experiments 
using RNA, appropriate volumes of THE Ambion® RNA Storage  
Job Plot Analysis. Fluorescence measurements were carried out at 25 °C on a HORIBA 
Jobin Yvon (Edison, NJ) FluoroMax-3 spectrofluorometer using a 250 µL quartz cell with 0.1 
cm path length. The concentrations of the DNA and ligand were varied in each sample whereas 
the sum of the concentrations (c0) was kept constant. All solution contained MOPS (20 mM; 
pH 7.0 ± 0.2) and NaCl (300 mM). The blanks, consisting of the same solutions with no DNA, 
were used to correct dilution effects. The fluorescence signal was measured with an excitation 
wavelength of 425 nm and emission wavelength was collected from 445 to 540 nm. The 
fluorescence intensity of the sample (F) and the blank (F0) at 463 nm for each mole fraction of 
ligand (XL) was used for the Job plot analysis. A Job plot was constructed by plotting the 
change in fluorescence (∆F = F0 – F) versus the ligand mole fraction. The stoichiometry was 
determined from the intercept of the two tangents aligned at the positions XL = 0.0 and 1.0. 
In Vitro Transcription. In vitro transcription assays were carried out as previously 
reported previously with minor modifications.75 Briefly, the ligands at each concentration were 
incubated with 15 ng of template DNA (linearized (CTG)74 plasmid or control DNA template), 
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0.5 mM each rNTPs, and 1X T7 transcription buffer (Biolab, 80 mM Tris pH 8.3, 10 mM 
MgCl2, 2 mM spermine, 0.1% Triton-X, 10 mM NaCl) at 37 oC for 3 h. After pre-incubation, 
0.5 U T7 RNA polymerase (Biolab) was added to the reaction mixture, and transcription was 
allowed for 1.5 h. The reaction was quenched by adding 7 µL of 8 M urea, 1 µL of denaturing 
dye (95% formamide, 5 mM EDTA, 0.025% each xylene cyanol and bromophenol blue) and 
2 µL of 10 µM HIV fs RNA, and then heating to 95 °C for 5 min. Of this solution, 15 µL was 
run on a 10% denaturing polyacrylamide gel in 1× TBE. The gel was stained with EtBr. Bands 
were quantified using ImageJ (NIH). 
Cytotoxicity Study. Cytotoxicity of compounds was studied using HeLa cells by 
following the protocol reported by Vichai and Kirtikara.126  Briefly, HeLa cells were prepared 
in a 96-well plate a day before the compound treatment. The ligand was added to each well to 
have serially diluted concentrations from 100 µM to 0.2 µM and incubated at 37oC for 72 h. 
Then, the cells were fixed and stained with sulforhodamine B (SRB). Bound SRB was 
dissolved by Tris base solution (pH 10.5) and the OD was measured at 510 nm. The percentage 
of cell death was plotted against concentrations of compounds. 
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Ligand 11. NaN(CN)2 (3.65 g, 40.8 mmol) was added to a stirred solution of 13 (2.75 g, 16.3 
mmol, prepared by treating a methanolic solution of 5-aminoindole with 1.5 equiv. HCl in 
Et2O) in DMF (27 mL) in a 50-mL round-bottomed flask. The reaction mixture was stirred at 
40 ºC for 4 h. DMF was removed and the residue was treated with H2O (50 mL) vigorously 
overnight. A gray solid precipitated and was collected by filtration and dried under high 
vacuum to give compound 14 (2.63 g, 89% yield), which was used for the next step without 
further purification. The characterization data were consistent with literature reported values:88 
1H NMR (400 MHz, DMSO-d6) δ 11.12 (s, 1 H), 8.86 (s, 1 H), 7.46 (s, 1 H), 7.35-7.33 (m, 2 
H), 6.94 (dd, J = 8.8 Hz, 2.0 Hz, 1 H), 6.74 (s, 2 H), 6.40 (s, 1 H). Boron trifluoride (9.4 mL, 
76 mmol) was added dropwise to a stirred suspension of 14 (2.63 g, 13.2 mmol) in DME (300 
mL) and stirred at 60 ºC for 4 h. The solvent was removed, and the residue was suspended in 
MeOH (30 mL) and treated with NH4OH (40 mL) for 2 h. The solvents were removed in vacuo 
and the residue was purified by column chromatography on 125 mL Al2O3 (activated, basic), 
eluting with gradient 5:1 to 1:1 (over 3 L) DCM:MeOH to afford 1.9 g (65%) of ligand 11 as 
a white to pale yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 11.55 (s, 1 H), 7.64 (d, J = 8.8 
Hz, 1 H), 7.43 (t, J = 2.8 Hz, 1 H), 7.03-7.00 (m, 2 H), 6.65 (brs, 2 H), 5.65 (s, 2 H); 13C NMR 

























40 ºC, 4 h
82%
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Ligand 17. NaN(CN)2 (1.52 g, 17.1 mmol) was added to a stirred solution of 15 (1.25 g, 6.84 
mmol, prepared by treating a methanolic solution of commercially-available 2-methyl-1H-
indol-5-amine with 1.5 equiv. HCl in Et2O) in DMF (12 mL) in a 50-mL round-bottomed flask. 
The reaction mixture was stirred at 40 ºC for 4 h. DMF was removed and the residue was 
treated with H2O (20 mL), sonicated briefly, and left stirring vigorously overnight. A gray solid 
precipitated and was collected by filtration and dried under high vacuum to give compound 16 
(1.19 g, 82% yield), which was used for the next step without further purification. 1H NMR 
(400 MHz, DMSO-d6) δ 10.92 (s, 1H), 8.82 (s, 1H), 7.30 (d, J = 2.0 Hz, 1H), 7.20 (d, J = 8.5 
Hz, 1H), 6.84 (dd, J = 8.5, 2.1 Hz, 1H), 6.72 (s, 2H), 6.09 (s, 1H), 2.36 (s, 3H). Boron trifluoride 
etherate (3.5 mL, 28.5 mmol) was added dropwise to a stirred suspension of 16 (1.27 g, 5.94 
mmol) in DME (115 mL) and stirred at 60 ºC for 4 h. The solvent was removed, dried 
overnight, and the residue was suspended in MeOH (12 mL) and treated with NH4OH (8 mL) 
for 2 h. The solvents were removed in vacuo and the residue was purified by column 
chromatography on 120 mL Al2O3 (activated, basic), eluting with gradient 7:1 to 2:1 (over 2 
L) DCM:MeOH to afford 0.89 g (71%) of ligand 17 as a pale yellow solid. 1H NMR (500 
MHz, DMSO-d6) δ 11.29 (s, 1H), 7.52 (d, J = 8.8 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.73 (s, 
1H), 6.52 (s, 2H), 5.56 (s, 2H), 2.43 (s, 3H).  
 
1-Methyl-5-nitro-1H-indole (19). To a stirred solution of 18 (1.0 g, 6.16 mmol) in 20 mL of 
anhydrous DMF in a 100-mL round-bottomed flask was added sodium hydride (60% in 
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(0.42 mL, 6.78 mmol) was added and stirred at r.t. overnight, monitoring by TLC (25:1 
DCM:MeOH, Rf = 0.5). The reaction was quenched with saturated aqueous ammonium 
chloride (35 mL) and extracted with EtOAc (2 x 40 mL). The organic layer was washed with 
5% aqueous lithium chloride (50 mL), H2O (50 mL), brine (100 mL), and dried with MgSO4 
and concentrated in vacuo to afford 1.04 g of 19 (96%) as a dark yellow powder. 1H NMR (500 
MHz, CDCl3) δ 8.59 (d, J = 2.0 Hz, 1 H), 8.13 (dd, J = 2.0, 9.0 Hz, 1 H), 7.34 (d, J = 9.0 Hz, 
1 H), 7.20 (d, J = 3.0 Hz, 1 H), 6.67 (dd, J = 0.5, 1.0, 3.0, 3.5 Hz, 1 H), 3.86 (s, 3 H).  
 
1-Methyl-1H-indol-5-amine (20). To a 100-mL round-bottomed flask containing 0.2 g of 
Pd/C (5%) carefully wetted with ca. 3 mL of methanol and a magnetic stir bar under an inert 
atmosphere was added a solution of 0.5 g (2.8 mmol) of 19 in 40 mL of methanol. Hydrogen 
gas was bubbled through the solution while stirring at r.t. for 1 h. The solution was vacuum-
filtered through a small Celite bed and the solvents were removed in vacuo to afford 0.41 g 
(quant.) of 20 as a brown powder. 1H NMR (500 MHz, CDCl3) δ 7.12 (dd, J = 12.1, 7.5 Hz, 2 
H), 6.84 (t, J = 1.6 Hz, 1 H), 6.77 (dd, J = 7.6, 1.5 Hz, 1 H), 6.54 (dd, J = 7.5, 1.5 Hz, 1 H), 
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Ligand 22. The title compound was prepared as described for ligand 11 from 0.31 g (2.1mmol) 
of 20, affording 0.32 g (72%) of 21 and 0.19 g (61%) of ligand 22 as a yellowish solid. 1H 
NMR (500 MHz, DMSO-d6) δ 8.11 – 8.03 (m, 2 H), 7.37 (d, J = 7.6 Hz, 1 H), 7.02 (d, J = 7.5 
Hz, 1 H), 5.38 (s, 2 H), 4.46 (s, 2 H).  
 
N-(2-(Dimethylamino)ethyl)-5-nitro-1H-indole-2-carboxamide (25). To a stirred solution 
of 0.5 g (2.43 mmol) of 23 in 6 mL of dioxane in a 25-mL round-bottomed flask was slowly 
added 6 mL of freshly distilled SOCl2. The mixture was refluxed at 105 ºC for 1.5 h and then 
the excess SOCl2 was distilled off; the last traces were removed azeotropically via co-
evaporation with DCM (4 x 15 mL). The crude was left under high vacuum for 1 h to afford 
the crude intermediate 24 as a dark yellow powder. Then it was dissolved in 7 mL of dioxane 
at r.t. and 1 mL (9.22 mmol) of N,N-dimethylethylenediamine was added. The mixture was 
stirred at RT overnight, monitoring by TLC on aluminum oxide (activated, basic) plates (25:1 
DCM:MeOH, Rf = 0.5). The solvents were removed, and the remaining crude solid was 
dissolved in EtOAc/H2O (200 mL) mixture and extracted with EtOAc (3 x 100 mL). The 
combined organic layers were washed with brine (100 mL), dried with MgSO4 and 
concentrated in vacuo and the crude was purified by column chromatography (~120 mL Al2O3, 
activated, basic) using 300:1-300:3 gradient eluent of DCM:MeOH. The product- containing 
fractions were combined and concentrated in vacuo to afford 0.64 g (95%) of 25 as a light-



























8.66 (t, J = 5.7 Hz, 1 H), 8.06 (dd, J = 9.1, 2.3 Hz, 1 H), 7.57 (d, J = 9.1 Hz, 1 H), 7.38 (d, J = 
0.9 Hz, 1 H), 3.39 (q, J = 6.5 Hz, 3 H), 2.42 (t, J = 6.7 Hz, 2 H), 2.19 (s, 6 H).  
 
5-Amino-N-(2-(dimethylamino)ethyl)-1H-indole-2-carboxamide (26). To a stirred solution 
of 0.46 g (1.66 mmol) of 25 in 25 mL of EtOH was added 3.75 g (16.6 mmol) of SnCl2•2H2O 
and refluxed (100 ºC) for 24 h, monitoring by TLC on aluminum oxide (activated, basic) plates 
(25:1 DCM:MeOH, Rf = 0.3). The solvents were removed and the residue was dissolved in 150 
mL of water and basified to pH 8 with aqueous NaHCO3 or 2M KOH. This was extracted with 
EtOAc (6 x 150 mL). The combined organic layers were washed with brine (100 mL), dried 
with MgSO4 and concentrated in vacuo and the crude was purified by column chromatography 
(~120 mL Al2O3, activated, basic) using 300:2 DCM:MeOH (MeOH contained 5% NH4OH 
v/v).The product-containing fractions were combined and concentrated in vacuo to afford 0.30 
g (74%) of 26 as a light brown powder. 1H NMR (500 MHz, DMSO-d6) δ 8.67 (s, 1 H), 7.33 
(d, J = 7.6 Hz, 1 H), 6.99 (d, J = 1.6 Hz, 1 H), 6.82 (t, J = 1.4 Hz, 1 H), 6.48 (dd, J = 7.5, 1.7 
Hz, 1 H), 4.26 (s, 2 H), 3.35 (d, J = 7.2 Hz, 2 H), 2.43 (t, J = 7.3 Hz, 2 H), 2.20 (s, 6 H).  
 
1. SnCl2•2H2O, EtOH
    reflux, 5 h
2. 2M HCl in Et2O





















50 ºC to 0 ºC
4 h, 82%29 30
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2-Iodo-4-nitroaniline (30). (Prepared from a reported procedure24 with slight modifications.) 
To a stirred solution of 1.38 g (10 mmol) of 29 in 4 mL of concentrated HCl and 30 mL of 
H2O in a 200-mL round-bottomed flask was added a solution of 3.41 g (21 mmol) of ICl in 6 
mL of concentrated HCl drop-wise over 1 h using a syringe pump. The mixture was stirred at 
50 ºC for 2.5 h, then at 0 ºC for 15 min. Two grams of Na2SO4 were added, and stirred at RT 
for 15 min. Diethyl ether (30 mL) was added and stirred for an additional 20 min. The aqueous 
layer was extracted with diethyl ether (2 x 70 mL), and the organic layers were washed once 
with NaHCO3 (50 mL), dried with MgSO4. The organic layers were concentrated and purified 
by column chromatography (~100 mL SiO2) using 15:1 hexanes:ethyl acetate, and monitored 
by TLC (5:1 hexanes:EtOAc, Rf = 0.30). The product-containing fractions were combined and 
concentrated in vacuo to afford 2.16 g (82%) of 30 as a brown crystalline solid.1H HMR (400 
MHz, CDCl3) 8.57 (d, J = 3Hz, 1H), 8.10 (dd, J = 3, 9Hz, 1H), 6.47 (d, J = 9 Hz, 1H), 4.80 (br 
d, 1H).  
 
Benzyl (3-(2-amino-5-nitrophenyl)prop-2-yn-1-yl)carbamate (31). To a stirred solution of 
0.505 g (1.91 mmol) of 30, 5.46 g (0.029 mmol) of CuI and 20.1 mg (0.029 mmol) of 
Pd(Ph3P)2Cl2 in 22 mL of TEA (22 mL) was added 1.30 g (6.86 mmol) of Cbz-protected 
propargyl amine drop-wise. The mixture was stirred at r.t. for 12 h, monitoring by TLC (5:1 

















by column chromatography (~100 mL SiO2) using an eluent gradient of 20:1 to 10:1 
hexanes:ethyl acetate over 1.5 L. The product-containing fractions were combined and 
concentrated in vacuo to afford 0.59 g (95%) of 31 as a dark orange solid. 1H NMR (500 MHz, 
CDCl3) δ 8.18 (d, J = 2.7 Hz, 1 H), 8.03 (dd, J = 9.0, 2.6 Hz, 1 H), 7.39 (d, J = 4.6 Hz, 5 H), 
6.65 (d, J = 9.1 Hz, 1H), 5.17 (s, 2 H), 5.03 (s, 2 H), 4.26 (d, J = 5.8 Hz, 2 H), 2.19 (s, 1H).  
 
Benzyl ((5-nitro-1H-indol-2-yl)methyl)carbamate (32). To a stirred solution of 0.606 g 
(1.86 mmol) of 31 in 8 mL of DMF was added 0.12 g (0.612 mmol) of CuI. The mixture was 
stirred at reflux for 4 h, then at r.t. for 16 h, monitoring the reaction by TLC (3:2 ethyl 
acetate:hexanes, Rf = 0.5). The solvent was removed in vacuo to leave a dark residue, which 
was purified by column chromatography (~100 mL SiO2) using an eluent 25:1 hexanes:ethyl 
acetate to afford 0.26 g (43%) of 32 as a dark orange oil. 1H NMR (500 MHz, CDCl3) δ 8.78 
(t, J = 1.6 Hz, 1 H), 7.94 – 7.85 (m, 2 H), 7.71 (d, J = 7.5 Hz, 1 H), 7.38 – 7.27 (m, 2 H), 6.55 
(d, J = 1.5 Hz, 1 H), 5.45 (s, 1 H), 5.03 (s, 2 H), 4.75 (s, 1 H), 4.46 (s, 1 H).  
 
2-(4-(2,6-Diamino-9H-purin-9-yl)butyl)isoindoline-1,3-dione (41). To a stirred solution of 
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round-bottomed flask was added 0.155 g (3.86 mmol) of a 60% suspension in oil of NaH and 
stirred at RT for 2 h. Then, 0.966 g (3.42 mmol) of N-(4-bromobutyl)phthalimide was added, 
and the mixture was stirred for 24 h. The reaction was monitored by TLC (silica gel plates, 
10:1 (v/v) DCM:MeOH, Rf = 0.4). The solvents were removed in vacuo, the remaining crude 
was sonicated in 1:1 (v/v) MeOH:H2O, and the solid was filtered off and washed with MeOH 
thoroughly, affording 0.443 g (1.26 mmol, 37%) of 41 as an off-white powder. 1H NMR (500 
MHz, DMSO-d6) δ 7.89 – 7.79 (m, 4H), 7.64 (d, J = 1.6 Hz, 1H), 6.62 (s, 2H), 5.75 (s, 2H), 
3.96 (t, J = 7.0 Hz, 2H), 3.59 (t, J = 7.2 Hz, 2H), 1.74 (p, J = 6.9 Hz, 2H), 1.54 (p, J = 7.2 Hz, 
2H). 
 
9-(4-Aminobutyl)-9H-purine-2,6-diamine (42). A solution of 0.443 g (1.26 mmol) of 41 in 
5 mL of a 1:1:1 (v/v) mixture of H2O:AcOH:HCl (conc.) in a 50-mL (24/40) round-bottomed 
flask equipped with a condenser was stirred at 100 ºC for 24 h. The reaction was monitored by 
TLC (silica gel plates, 10:1 (v/v) DCM:MeOH). Then, some of the solvents were removed in 
vacuo, producing a white precipitate (phthalic acid). This precipitate was filtered off and the 
remaining solvents were removed in vacuo. The crude was dissolved in water, and the solvents 
were removed in vacuo (this was repeated two times). The crude was dissolved in minimal 
water (ca. 7 mL), basified with 3M KOH, and then saturated with NaCl powder. The resulting 
suspension was transferred to a separatory funnel, and extracted multiple times with 10:1 (v/v) 


















vacuo, affording 0.237 g (1.07 mmol, 85%) 42 as a clear oil. 1H NMR (500 MHz, DMSO-d6) 
δ 7.62 (d, J = 1.6 Hz, 1H), 6.63 (s, 2H), 5.72 (s, 2H), 3.94 (t, J = 7.0 Hz, 2H), 2.69 (t, J = 7.2 
Hz, 2H), 1.74 (p, J = 6.9 Hz, 2H), 1.47 (p, J = 7.2 Hz, 2H). 
  
9-Chloro-N-(2-(dimethylamino)ethyl)acridine-4-carboxamide (44). To the 65-mL (14/20) 
round-bottomed flask (sealed with a septum and equipped with a magnetic stir bar) containing 
crude 43 under argon (4.06 mmol), which was carefully collected avoiding exposure to air and 
moisture as much as possible, was added 4 mL of anhydrous DCM via a syringe and needle, 
followed by 1 mL of DIPEA and then quickly placed in an ice bath. Additional DIPEA (ca. 
0.8 mL) was added to ensure the reaction remained at a basic pH. N,N-
Dimethylethylenediamine (0.256 g, 2.91 mmol) was dissolved in 4 mL of anhydrous DCM 
and was cannulated into the round-bottomed flask at once, and its glass vial was rinsed with 4 
additional mL of anhydrous DCM and also transferred to the round-bottomed flask. The 
resulting mixture was periodically sonicated to break apart some of the solid precipitates. The 
mixture was stirred at 4 ºC for 1 h, then at room temperature overnight, resulting in a dark 
orange/yellow turbid solution. The reaction was monitored by TLC using silica gel plates and 
a mixture of 10:1 DCM:MeOH. The mixture was diluted with 5 mL of methanol, vacuum 
filtered through a Celite pad and rinsed with 15 mL of methanol, and the filtrate was 
concentrated in vacuo leaving the crude as a dark orange solid. The crude was dissolved in ca. 



















solvent conditions (column was 4.5 cm in diameter, 26 cm in height). The column was eluted 
with a solvent gradient of 500:5 to 500:40 DCM:MeOH over 3 L, collecting 200-mL fractions 
(product started eluting after ca. 1.5 L) and monitoring by TLC (Rf = 0.48). The fractions 
containing the product were concentrated and repurified using the same conditions above, 
affording 0.515 g (1.57 mmol, 54%) of 44 as a dark yellow solid. 1H NMR (500 MHz, 
Chloroform-d) δ 11.44 (s, 1H), 9.00 (dd, J = 7.1, 1.5 Hz, 1H), 8.54 (dd, J = 8.7, 1.5 Hz, 1H), 
8.39 (dd, J = 8.7, 1.3 Hz, 1H), 8.11 (dd, J = 8.7, 1.0 Hz, 1H), 7.85 (ddd, J = 8.3, 6.6, 1.3 Hz, 
1H), 7.77 – 7.62 (m, 2H), 3.61 (t, J = 5.1 Hz, 2H), 2.47 (t, J = 5.1 Hz, 2H), 2.29 (s, 6H). 
 
Ligand 39. To a stirred solution of 0.233 g (0.71 mmol) of 44 in 5 mL of anhydrous DMF in 
a 25-mL (14/20) round-bottomed flask was added 0.2 mL of DIPEA and 0.137 g (0.62 mmol) 
of 42 and stirred at 70 ºC for 16 h. The reaction was monitored by TLC (Al2O3, 10:1 (v/v) 
DCM:MeOH, Rf = 0.5). The solvents were removed in vacuo and the crude was further dried 
under high vacuum for a few hours, leaving a thick orange/brown oily residue. The residue 
was suspended in 10 mL of water and 6M aq. HCl until the pH was acidic, turning to a dark 
orange solution with some precipitate. The precipitate was filtered off through a syringe filter 
(0.2 micron) and loaded onto a C18-reversed-phase silica gel column that was primed with 550 
mL of 500:50:0.5 (v/v) H2O:MeOH:HCl (conc.). The column was eluted with a solvent 
gradient of 500:50:0.5 to 500:200:0.7 H2O:MeOH:HCl (conc.). To monitor by TLC, 6 drops 
DIPEA, DMF































of the corresponding fraction were mixed with 1-2 drops of MeOH:NH4OH (9:1, v/v) and the 
solution was spotted onto an Al2O3 TLC plate (basic) and developed with a mixture of 10:1 
DCM:MeOH (Rf = 0.5). The fractions containing the product were combined and concentrated 
in vacuo to afford 0.193 g (0.31 mmol, 50%) of 39 as a yellow solid. 1H NMR (500 MHz, 
DMSO-d6) δ 13.52 (s, 1H), 12.36 (s, 0H), 10.50 (s, 1H), 10.25 (s, 0H), 9.66 (s, 1H), 8.66 (d, J 
= 7.4 Hz, 0H), 8.50 (s, 1H), 8.11 – 7.96 (m, 2H), 7.63 (s, 1H), 7.57 (s, 1H), 7.45 (s, 1H), 4.11 
(s, 1H), 3.78 (q, J = 5.7 Hz, 1H), 3.39 (s, 0H), 2.88 (d, J = 4.4 Hz, 3H), 1.91 (s, 2H). 
 
 
Ligand 46.62 To a stirred solution of 7.05 g (80 mmol) of 1,4-diaminobutane at 110 ºC in a 
two-necked 300-mL (24/40) round-bottomed flask was added 1.05 g (7.21 mmol) of 45 
(dissolved in 100 mL of EtOH) dropwise over 4 h. The mixture was refluxed for 18 h, and then 
the solvents were removed in vacuo and the residue was further dried under high vacuum 
overnight. The white crude solid was adsorbed onto silica and dry-loaded onto a silica column, 
packed with 100:12:1 (v/v) DCM:MeOH:NH4OH. The column was eluted on a gradient up to 
100:20:2 (v/v) DCM:MeOH:NH4OH under 3 psi and checked by TLC (silica gel plates, 9:1 
(v/v) MeOH:NH4OH, Rf = 0.4).The fractions containing the product were collected and 
concentrated, affording 0.825 g (4.18 mmol, 58%) of 46 as a white solid. 1H NMR (500 MHz; 
DMSO-d6) 7.89 (s, 2H), 6.48 (t, J = 5.8, 1H), 6.00 (d, J = 80.1, 4H), 3.18 (q, J = 6.1, 2H), 




















Ligand 47. The title compound was prepared in similar conditions as described for compound 
39 from 0.302 g (1.12 mmol) of 44 and 0.201 g (1.02 mmol) of 46, affording 0.336 g (0.562 

















70 ºC, 16 h




















Compound 52a. To a 200-mL (24/40) round-bottomed flask equipped with a magnetic stir bar 
was added 51124 (2.05 g, 11.8 mmol), 2.1 mL (12 mmol) of DIPEA, and 55 mL of MeCN. 
While stirring at room temperature, tert-butyl(3-aminopropyl)carbamate (2.05 g, 11.8 mmol) 
was added and the solution was stirred for 12 h. The solution was initially colorless and white 
precipitate began to form after a few hours. The precipitate was filtered off and rinsed with 
water (30 mL) and dried under nitrogen to afford 3.12 g (10.1 mmol, 86%) of 52a as a white 
solid. 
Compound 53a. To a 250-mL (24/40) 2-necked round-bottomed flask equipped with a 
magnetic stir bar and a condenser was added 8.5 mL (102.4 mmol) of 1,3-diaminopropane and 
heated to 110 ºC. Compound 52a (3.10 g, 10.2 mmol) was dissolved in 100 mL of warm 







































































1. TFA/DCM (1:3, v/v)
    RT, 35 min, quant.
2. DMF, DIPEA
    65 ºC, 36 h




refluxing mixture. After refluxing for 16 h, the solvents were removed in vacuo and the crude 
was adsorbed onto silica gel and dry-loaded on a silica gel column slurry-packed with 100:10:1 
DCM:MeOH:NH4OH (column was 4.5 cm in diameter, 28 cm in height), eluted on a solvent 
gradient from 100:10:1 to 100:20:2 of DCM:MeOH:NH4OH over 2 L and monitoring by TLC 
(silica gel plates, using 9:1 MeOH:NH4OH, Rf = 0.45). The fractions containing the product 
were collected and concentrated, affording 1.91 g (5.61 mmol, 55%) of 53a as an off-white 
solid. 
Compound 54a. To a 65 mL (14/20) round-bottomed flask (sealed with a septum and equipped 
with a magnetic stir bar) containing crude 43 under argon (4.68 mmol, prepared from 1.12 g 
of 5464), which was carefully collected avoiding exposure to air and moisture as much as 
possible, was added 4 mL of anhydrous DCM via a syringe and needle, followed by 1 mL of 
DIPEA and then quickly placed in an ice bath. Compound 53a (1.00 g, 2.94 mmol) was 
dissolved in 4 mL of anhydrous DCM and was cannulated into the round-bottomed flask at 
once, and its glass vial was rinsed with 4 additional mL of anhydrous DCM and also transferred 
to the round-bottomed flask. An additional 0.8 mL of DIPEA was added to ensure the reaction 
remained at a basic pH. The resulting mixture was periodically sonicated to break apart some 
of the solid precipitates. The mixture was stirred at 4 ºC for 1 h, then at room temperature 
overnight, resulting in a dark orange/yellow turbid solution. The reaction was monitored by 
TLC using silica gel plates and a mixture of 10:1 DCM:MeOH. The mixture was diluted with 
5 mL of methanol, vacuum filtered through a Celite pad and rinsed with 15 mL of methanol, 
and the filtrate was concentrated in vacuo leaving the crude as a dark orange solid. The crude 
was dissolved in ca. 5 mL of 100:3.5 DCM:MeOH and loaded onto a silica gel column packed 
with the same solvent conditions (column was 4.5 cm in diameter, 26 cm in height). The 
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column was eluted with a solvent gradient of 500:17.5 to 500:40 DCM:MeOH over 3 L, 
collecting 200-mL fractions (product started eluting after ca. 1.5 L) and monitoring by TLC 
(Rf = 0.38). The fractions containing the product were concentrated and repurified using the 
same conditions above, affording 1.40 g (2.41 mmol, 82%) of 54a as a dark yellow solid. 
Macrocycle A3D3. To a 100-mL (24/40) oven-dried round-bottomed flask equipped with a 
magnetic stir bar and sealed with a rubber septum was added 54a (0.387 g, 0.67 mmol) and 
kept under high vacuum for 1 h, then filled with nitrogen. Then, 25 mL of anhydrous DCM 
was added via a cannula and, while stirring vigorously at room temperature, 10 mL of TFA 
was added at once. The bright yellow solution was stirred for 35 min (completion of the 
deprotection was verified by ESI-MS) and then the solvents were removed in vacuo, leaving a 
dark yellow/orange oily residue that was further dried in high vacuum for a few hours. The 
crude was dissolved in ca. 6 mL of anhydrous DMF and 0.7 mL of anhydrous DIPEA was 
quickly added and stirred for 5–10 min (0.5 mL was needed to reach pH 9, 0.2 mL added for 
the reaction). The dark yellow solution was transferred to a 1-L (24/40) oven-dried round-
bottomed flask equipped with a large magnetic stir bar via a cannula, and then ca. 550 mL of 
anhydrous DMF was further added via a cannula (final [54a] ≈ 1 mM). The light-yellow 
solution (bright blue solution under 365 nm light) was stirred at 65 ºC for 36 h, eventually 
turning to a deep yellow color (very bright green solution under 365 nm light). The cyclization 
was very sensitive to solvent dryness, easily failing if the solvent was not dry, and to the 
solution pH before dilution (very important that it was basic). The solvents were removed in 
vacuo and the crude was further dried under high vacuum for a few hours, leaving a thick 
orange/brown oily residue. The residue was suspended in ca. 20 mL of water and 6M aq. HCl 
was added until pH < 2, resulting in a dark orange suspension. The precipitate was filtered off 
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through a KimWipe-filled glass Pasteur pipette and the resulting dark orange solution was 
loaded onto a C18-reversed-phase silica gel column that was primed with 550 mL of 500:50:0.5 
(v/v) H2O:MeOH:HCl (conc.). The column was eluted with a solvent gradient of 500:50:0.5 
to 500:200:0.7 H2O:MeOH:HCl (conc.) for 3 L. To monitor by TLC, a few drops of the 
corresponding fraction were mixed with 1–2 drops of MeOH:NH4OH (9:1, v/v) and the 
solution was spotted onto an Al2O3 TLC plate (basic) using a freshly hand-custom-made 
capillary spotter from a Pasteur pipette and developed with a mixture of 10:1 DCM:MeOH (Rf 
= 0.5). The fractions containing the product were combined and concentrated in vacuo to afford 





Compound 53c. The title compound was prepared in similar conditions as described for 
compound 53a from 1.05 g (3.32 mmol) of 52a and 4 mL (40 mmol) of 1,4-diaminobutane, 
affording 0.611 g (1.7 mmol, 50%) of 53c as an off-white solid. 
Compound 54c. The title compound was prepared in similar conditions as described for 
compound 54a from 1.055 g (4.41 mmol) of 43 and 0.978 g (2.76 mmol) of 53c, affording 
0.672 g (1.13 mmol, 41%) of 54c as a dark yellow solid. 
Macrocycle A3D4. The title compound was prepared in similar as described for macrocycle 
A3D3 from 0.37 g (0.62 mmol) of 54c, affording 0.041 g (0.08 mmol, 12%) of A4D3 as a 
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Compound 52b. To a 200-mL (24/40) round-bottomed flask equipped with a magnetic stir 
bar was added 51 (1.65 g, 10 mmol), 2.1 mL (12 mmol) of DIPEA, and 55 mL of MeCN. 
While stirring at room temperature, tert-butyl (4-aminobutyl)carbamate (1.88 g, 10 mmol) was 
added and the solution was stirred for 12 h. The solution was initially colorless and white 
precipitate began to form after a few hours. The precipitate was filtered off and rinsed with 
water (30 mL) and dried under nitrogen to afford 2.59 g (8.2 mmol, 82%) of 52b as a white 
solid. 
Compound 53b. The title compound was prepared in similar conditions as described for 
compound 53a from 5.28 g (17.1 mmol) of 52b and 14.3 mL (171 mmol) of 1,3-
diaminopropane, affording 3.39 g (9.57 mmol, 56%) of 59 as an off-white solid. 
Compound 54b. The title compound was prepared in similar conditions as described for 
compound 54a from 1.03 g (4.31 mmol) of 43 and 0.995 g (2.81 mmol) of 53b, affording 0.564 
g (0.95 mmol, 34%) of 54b as a dark yellow solid. 
Macrocycle A4D3. The title compound was prepared in similar as described for macrocycle 
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Compound 53d. The title compound was prepared in similar conditions as described for compound 
53a from 3.48 g (11 mmol) of 52b and 11 mL (110 mmol) of 1,4-diaminobutane, affording 3.07 g (8.33 
mmol, 77%) of 53d as a white solid. 
Compound 54d. The title compound was prepared in similar conditions as described for compound 
54a from 4.71 mmol of 43 and 1.23 g (3.36 mmol) of 53d, affording 0.564 g (0.95 mmol, 34%) of 54d 
as a dark yellow solid. 
Macrocycle A4D4. The title compound was prepared in similar as described for macrocycle A3D3 
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1. TFA/DCM (1:3, v/v)
    RT, 35 min, quant.
2. DMF, DIPEA
    65 ºC, 36 h








Compound 52c. The title compound was prepared in similar conditions as described for 
compound 52a from 1.94 g (11.8 mmol) of 51 and 2.05 g (11.8 mmol) of tert-butyl (5-
aminopentyl)carbamate, affording 3.12 g (10.1 mmol, 86%) of 52c as a white solid. 
Compound 53e. The title compound was prepared in similar conditions as described for 
compound 53a from 3.10 g (10.2 mmol) of 52c and 8.5 mL (102.4 mmol) of 1,5-
diaminopentane, affording 1.91 g (5.61 mmol, 55%) of 53e as an off-white solid. 
Compound 54e. The title compound was prepared in similar conditions as described for 
compound 54a from 1.12 g (4.68 mmol) of 43 and 1.00 g (2.94 mmol) of 53e, affording 1.40 
g (2.41 mmol, 82%) of 54e as a dark yellow solid. 
Macrocycle A5D5. The title compound was prepared in similar as described for macrocycle 
A3D3 from 0.387 g (0.67 mmol) of 54e, affording 0.16 g (0.31 mmol, 47%) of A5D5 as a dark 
yellow solid. 
4.3. Appendix 
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Figure 35. 1H NMR spectrum of ligand A3D3. 
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Figure 49. 13C NMR spectrum of ligand A5D5. 
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4.3.2. ITC Isotherms 
 
Figure 50. ITC isotherms of the macrocyclic ligands with dsDNA. 
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Figure 50. (cont.) 
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Figure 51. ITC isotherms of the macrocyclic ligands with d(CTG)2. 
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Figure 51. (cont.) 
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Figure 52. ITC isotherms of the macrocyclic ligands with d(CCG)2. 
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Figure 52. (cont.) 
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Figure 53. ITC isotherms of the macrocyclic ligands with r(CUG)2. 

































































Figure 53. (cont.) 
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Figure 54. ITC isotherms of the macrocyclic ligands with d(CAG)2. 
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Figure 54. (cont.) 
 108 
REFERENCES 
(1) Lerman, L. S. J. Mol. Biol. 1961, 3, 18. 
(2) Tsai, C.-C.; Jain, S. C.; Sobell, H. M. Proc. Natl. Acad. Sci. U.S.A. 1975, 72 (2), 
628. 
(3) Shieh, H.-S.; Berman, H. M.; Dabrow, M.; Neidle, S. Nucleic Acids Research 
1980, 8 (1), 85. 
(4) Hollstein, U. Chem. Rev. 1974, 74 (6), 625. 
(5) Waring, M. J.; Wakelin, L. P. G. Nature 1974, 252 (5485), 653. 
(6) Arcamone, F.; Penco, S.; Orezzi, P.; Nicolella, V.; Pirelli, A. Nature 1964, 203 
(494), 1064. 
(7) Small Molecule DNA and RNA Binders; Demeunynck, M., Bailly, C., Wilson, W. 
D., Eds.; Wiley-VCH: Weinheim, 2003. 
(8) Paul, A.; Bhattacharya, S. Current Science 2012. 
(9) Xie, Y.; Tam, V. K.; Tor, Y. In The Chemical Biology of Nucleic Acids; Mayer, G., 
Ed.; The Chemical Biology of Nucleic Acids; John Wiley & Sons, Ltd: Chichester, 
UK, 2010; Vol. 171, pp 115–140. 
(10) Escudé, C.; Garestier, T.; Sun, J.-S. Drug interaction with triple-helical nucleic 
acids; Methods in Enzymology; Elsevier, 2001; Vol. 340, pp 340–357. 
(11) Siddiqui-Jain, A.; Grand, C. L.; Bearss, D. J.; Hurley, L. H. Proc. Natl. Acad. Sci. 
U.S.A. 2002, 99 (18), 11593. 
(12) Saenger, W. In Principles of Nucleic Acid Structure; Springer Advanced Texts in 
Chemistry; Springer New York: New York, NY, 1984; pp 350–367. 
(13) Crothers, D. M. Biopolymers 1968, 6 (4), 575. 
(14) Dervan, P. B. Bioorganic & Medicinal Chemistry 2001, 9 (9), 2215. 
(15) Dervan, P. B. Science 1986, 232 (4749), 464. 
(16) Dervan, P. B.; Edelson, B. S. Curr. Opin. Struct. Biol. 2003, 13 (3), 284. 
(17) Mrksich, M.; Parks, M. E.; Dervan, P. B. J. Am. Chem. Soc. 1994, 116 (18), 7983. 
(18) Chemical Biology of Nucleic Acids; Erdmann, V. A., Markiewicz, W. T., 
Barciszewski, J., Eds.; Springer Berlin Heidelberg: Berlin, Heidelberg, 2014. 
 109 
(19) Granzhan, A.; Kotera, N.; Teulade-Fichou, M.-P. Chem. Soc. Rev. 2014, 43 (10), 
3630. 
(20) De Bont, R.; van Larebeke, N. Mutagenesis 2004, 19 (3), 169. 
(21) Kunkel, T. A.; Erie, D. A. Annu. Rev. Biochem. 2005, 74, 681. 
(22) Branzei, D.; Foiani, M. Nat. Rev. Mol. Cell Biol. 2008, 9 (4), 297. 
(23) Brown, J.; Brown, T.; Fox, K. R. Biochemical Journal 2001, 354 (3), 627. 
(24) Neidle, S. In Principles of Nucleic Acid Structure; Elsevier, 2008; pp 132–203. 
(25) Jackson, B. A.; Barton, J. K. J. Am. Chem. Soc. 1997, 119 (52), 12986. 
(26) Jackson, B. A.; Alekseyev, V. Y.; Barton, J. K. Biochemistry 1999, 38 (15), 4655. 
(27) Erkkila, K. E.; Odom, D. T.; Barton, J. K. Chem. Rev. 1999, 99 (9), 2777. 
(28) Nakatani, K. Bull. Chem. Soc. Jpn. 2009, 82 (9), 1055. 
(29) Teulade-Fichou, M.-P.; Vigneron, J.-P.; Lehn, J.-M. Supramolecular Chemistry 
1995, 5 (2), 139. 
(30) David, A.; Bleimling, N.; Beuck, C.; Lehn, J.-M.; Weinhold, E.; Teulade-Fichou, 
M.-P. ChemBioChem 2003, 4 (12), 1326. 
(31) Granzhan, A.; Largy, E.; Saettel, N.; Teulade-Fichou, M.-P. Chem. Eur. J. 2009, 
16 (3), 878. 
(32) Mirkin, S. M. Curr. Opin. Struct. Biol. 2006, 16 (3), 351. 
(33) Kim, J. C.; Mirkin, S. M. Current Opinion in Genetics & Development 2013, 23 
(3), 280. 
(34) McMurray, C. T. Nat. Rev. Genet. 2010, 11 (11), 786. 
(35) Pearson, C. E.; Edamura, K. N.; Cleary, J. D. Nat. Rev. Genet. 2005, 6 (10), 729. 
(36) Mirkin, S. M. Nature 2007, 447 (7147), 932. 
(37) Schoser, B.; Timchenko, L. T. Curr. Genomics 2010, 11 (2), 77. 
(38) Brook, J. D.; McCurrach, M. E.; Harley, H. G.; Buckler, A. J.; Church, D.; 
Aburatani, H.; Hunter, K.; Stanton, V. P.; Thirion, J.-P.; Hudson, T.; Sohn, R.; 
Zemelman, B.; Snell, R. G.; Rundle, S. A.; Crow, S.; Davies, J.; Shelbourne, P.; 
Buxton, J.; Jones, C.; Juvonen, V.; Johnson, K.; Harper, P. S.; Shaw, D. J.; 
Housman, D. E. Cell 1992, 68 (4), 799. 
 110 
(39) Liquori, C. L.; Ricker, K.; Moseley, M. L.; Jacobsen, J. F.; Kress, W.; Naylor, S. 
L.; Day, J. W.; Ranum, L. P. W. Science 2001, 293 (5531), 864. 
(40) Richards, R. I. Hum. Mol. Genet. 2001, 10 (20), 2187. 
(41) La Spada, A. R.; Taylor, J. P. Nat. Rev. Genet. 2010, 11 (4), 247. 
(42) López Castel, A.; Cleary, J. D.; Pearson, C. E. Nat. Rev. Mol. Cell Biol. 2010, 11 
(3), 165. 
(43) Liu, G.; Leffak, M. Cell & bioscience 2012. 
(44) Pearson, C. E.; Sinden, R. R. Biochemistry 1996, 35 (15), 5041. 
(45) Ohshima, K.; Wells, R. D. J. Biol. Chem. 1997, 272 (27), 16798. 
(46) Osborne, R. J.; Thornton, C. A. Hum. Mol. Genet. 2006, 15 Spec No 2 (Review 
Issue 2), R162. 
(47) Kuyumcu-Martinez, N. M.; Wang, G.-S.; Cooper, T. A. Molecular Cell 2007, 28 
(1), 68. 
(48) Childs-Disney, J. L.; Stepniak-Konieczna, E.; Tran, T.; Yildirim, I.; Park, H.; 
Chen, C. Z.; Hoskins, J. W.; Southall, N.; Marugan, J. J.; Patnaik, S.; Zheng, W.; 
Austin, C. P.; Schatz, G. C.; Sobczak, K.; Thornton, C. A.; Disney, M. D. Nat 
Commun 2013, 4, 2044. 
(49) Kalsotra, A.; Singh, R. K.; Gurha, P.; Ward, A. J.; Creighton, C. J.; Cooper, T. A. 
Cell Reports 2014, 6 (2), 336. 
(50) Moseley, M. L.; Zu, T.; Ikeda, Y.; Gao, W.; Mosemiller, A. K.; Daughters, R. S.; 
Chen, G.; Weatherspoon, M. R.; Clark, H. B.; Ebner, T. J.; Day, J. W.; Ranum, L. 
P. W. Nature Genetics 2006, 38 (7), 758. 
(51) Zu, T.; Gibbens, B.; Doty, N. S.; Gomes-Pereira, M.; Huguet, A.; Stone, M. D.; 
Margolis, J.; Peterson, M.; Markowski, T. W.; Ingram, M. A. C.; Nan, Z.; Forster, 
C.; Low, W. C.; Schoser, B.; Somia, N. V.; Clark, H. B.; Schmechel, S.; Bitterman, 
P. B.; Gourdon, G.; Swanson, M. S.; Moseley, M.; Ranum, L. P. W. Proc. Natl. 
Acad. Sci. U.S.A. 2011, 108 (1), 260. 
(52) Kanadia, R. N.; Shin, J.; Yuan, Y.; Beattie, S. G.; Wheeler, T. M.; Thornton, C. A.; 
Swanson, M. S. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (31), 11748. 
(53) Gareiss, P. C.; Sobczak, K.; McNaughton, B. R.; Palde, P. B.; Thornton, C. A.; 
Miller, B. L. J. Am. Chem. Soc. 2008, 130 (48), 16254. 
(54) Warf, M. B.; Nakamori, M.; Matthys, C. M.; Thornton, C. A.; Berglund, J. A. 
Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (44), 18551. 
 111 
(55) Coonrod, L. A.; Nakamori, M.; Wang, W.; Carrell, S.; Hilton, C. L.; Bodner, M. J.; 
Siboni, R. B.; Docter, A. G.; Haley, M. M.; Thornton, C. A.; Berglund, J. A. ACS 
Chem. Biol. 2013, 8 (11), 2528. 
(56) Hagihara, M.; Nakatani, K. Nucleic Acids Symposium Series 2006, 50 (1), 147. 
(57) Cinesi, C.; Aeschbach, L.; Yang, B.; Dion, V. Nat Commun 2016, 7, 13272. 
(58) Gomes-Pereira, M.; Monckton, D. G. Nucleic Acids Research 2004, 32 (9), 2865. 
(59) Hashem, V. I.; Pytlos, M. J.; Klysik, E. A.; Tsuji, K.; Khajavi, M.; Khajav, M.; 
Ashizawa, T.; Sinden, R. R. Nucleic Acids Research 2004, 32 (21), 6334. 
(60) Yang, Z.; Lau, R.; Marcadier, J. L.; Chitayat, D.; Pearson, C. E. Am. J. Hum. 
Genet. 2003, 73 (5), 1092. 
(61) Scrudato, Lo, M.; Poulard, K.; Klein, A.; Tomé, S.; Martin, S.; Gourdon, G.; 
Furling, D.; Buj-Bello, A. Neuromuscular Disorders 2017, 27, S181. 
(62) Arambula, J. F.; Ramisetty, S. R.; Baranger, A. M.; Zimmerman, S. C. Proc. Natl. 
Acad. Sci. U.S.A. 2009, 106 (38), 16068. 
(63) Wong, C.-H.; Nguyen, L.; Peh, J.; Luu, L. M.; Sanchez, J. S.; Richardson, S. L.; 
Tuccinardi, T.; Tsoi, H.; Chan, W. Y.; Chan, H. Y. E.; Baranger, A. M.; 
Hergenrother, P. J.; Zimmerman, S. C. J. Am. Chem. Soc. 2014, 136 (17), 6355. 
(64) Jahromi, A. H.; Nguyen, L.; Fu, Y.; Miller, K. A.; Baranger, A. M.; Zimmerman, 
S. C. ACS Chem. Biol. 2013, 8 (5), 1037. 
(65) Jahromi, A. H.; Fu, Y.; Miller, K. A.; Nguyen, L. J. Med. Chem. 2013, 56 (23), 
9471. 
(66) Wheeler, T. M.; Sobczak, K.; Lueck, J. D.; Osborne, R. J.; Lin, X.; Dirksen, R. T.; 
Thornton, C. A. Science 2009, 325 (5938), 336. 
(67) Parkesh, R.; Childs-Disney, J. L.; Nakamori, M.; Kumar, A.; Wang, E.; Wang, T.; 
Hoskins, J. W.; Tran, T.; Housman, D.; Thornton, C. A.; Disney, M. D. J. Am. 
Chem. Soc. 2012, 134 (10), 4731. 
(68) Garcia-Lopez, A.; Llamusí, B.; Orzáez, M.; Pérez-Payá, E.; Artero, R. D. Proc. 
Natl. Acad. Sci. U.S.A. 2011, 108 (29), 11866. 
(69) Lian, C.; Robinson, H.; Wang, A. H.-J. J. Am. Chem. Soc. 1996, 118 (37), 8791. 
(70) Childs-Disney, J. L.; Hoskins, J. W.; Rzuczek, S. G.; Thornton, C. A.; Disney, M. 
D. ACS Chem. Biol. 2012, 7 (5), 856. 
(71) Disney, M. D.; Lee, M. M.; Pushechnikov, A.; Childs-Disney, J. L. ChemBioChem 
2010, 11 (3), 375. 
 112 
(72) Lee, M. M.; Childs-Disney, J. L.; Pushechnikov, A.; French, J. M.; Sobczak, K.; 
Thornton, C. A.; Disney, M. D. J. Am. Chem. Soc. 2009, 131 (47), 17464. 
(73) Wong, C.-H.; Richardson, S. L.; Ho, Y.-J.; Lucas, A. M. H.; Tuccinardi, T.; 
Baranger, A. M.; Zimmerman, S. C. ChemBioChem 2012, 13 (17), 2505. 
(74) Marcheschi, R. J.; Tonelli, M.; Kumar, A.; Butcher, S. E. ACS Chem. Biol. 2011, 6 
(8), 857. 
(75) Nguyen, L.; Luu, L. M.; Peng, S.; Serrano, J. F.; Chan, H. Y. E.; Zimmerman, S. C. 
J. Am. Chem. Soc. 2015, 137 (44), 14180. 
(76) Luu, L. M.; Nguyen, L.; Peng, S.; Lee, J.; Lee, H. Y.; Wong, C.-H.; Hergenrother, 
P. J.; Chan, H. Y. E.; Zimmerman, S. C. ChemMedChem 2016, 11 (13), 1428. 
(77) Mooers, B. H. M.; Logue, J. S.; Berglund, J. A. Proc. Natl. Acad. Sci. U.S.A. 2005, 
102 (46), 16626. 
(78) Chen, C. Z.; Sobczak, K.; Hoskins, J. W.; Southall, N.; Marugan, J. J.; Zheng, W.; 
Thornton, C. A.; Austin, C. P. Anal Bioanal Chem 2012, 402 (5), 1889. 
(79) Ho, Y.-J. LEAD COMPOUND DISCOVERY FOR MYOTONIC DYSTROPHY, 
2013, pp 1–66. 
(80) Mao, C.; Flavin, K. G.; Wang, S.; Dodson, R.; Ross, J.; Shapiro, D. J. Analytical 
Biochemistry 2006, 350 (2), 222. 
(81) Kuyper, L. F.; Baccanari, D. P.; Jones, M. L.; Hunter, R. N.; Tansik, R. L.; Joyner, 
S. S.; Boytos, C. M.; Rudolph, S. K.; Knick, V.; Wilson, H. R.; Caddell, J. M.; 
Friedman, H. S.; Comley, J.; Stables, J. N. J. Med. Chem. 1996, 39 (4), 892. 
(82) Guan, J.; Zhang, Q.; O'Neil, M.; Obaldia, N.; Ager, A.; Gerena, L.; Lin, A. J. 
Antimicrob. Agents Chemother. 2005, 49 (12), 4928. 
(83) Blandamer, M. J. Biocalorimetry: Applications of Calorimetry in the Biological 
Sciences; Ladbury, J. E., Chowdhry, B. Z., Eds.; Wiley: Chichester, 1998. 
(84) Brown, A. IJMS 2009, 10 (8), 3457. 
(85) Freiburger, L.; Auclair, K.; Mittermaier, A. Methods 2015, 1. 
(86) Hunter, C. A.; Anderson, H. L. Angew. Chem. Int. Ed. 2009, 48 (41), 7488. 
(87) Turnbull, W. B.; Daranas, A. H. J. Am. Chem. Soc. 2003, 125 (48), 14859. 
(88) Chen, J.; Kassenbrock, A.; Li, B. X.; Xiao, X. Med. Chem. Commun. 2013, 4 (9), 
1275. 
(89) Roberts, R. J.; Cheng, X. Annu. Rev. Biochem. 1998, 67 (1), 181. 
 113 
(90) Roberts, R. J. Cell 1995, 82 (1), 9. 
(91) Priyakumar, U. D.; MacKerell, A. D. Chem. Rev. 2006, 106 (2), 489. 
(92) Pan, B.; Sundaralingam, M. International Journal of Quantum Chemistry 1999, 75 
(3), 275. 
(93) Tubbs, J. L.; Latypov, V.; Kanugula, S.; Butt, A.; Melikishvili, M.; Kraehenbuehl, 
R.; Fleck, O.; Marriott, A.; Watson, A. J.; Verbeek, B.; McGown, G.; Thorncroft, 
M.; Santibanez-Koref, M. F.; Millington, C.; Arvai, A. S.; Kroeger, M. D.; 
Peterson, L. A.; Williams, D. M.; Fried, M. G.; Margison, G. P.; Pegg, A. E.; 
Tainer, J. A. Nature 2009, 459 (7248), 808. 
(94) Weidmann, A. G.; Komor, A. C.; Barton, J. K. Comments on Inorganic Chemistry 
2014, 34 (3-4), 114. 
(95) Spies, M. A.; Schowen, R. L. J. Am. Chem. Soc. 2002, 124 (47), 14049. 
(96) Bando, T.; Fujimoto, J.; Minoshima, M.; Shinohara, K.-I.; Sasaki, S.; Kashiwazaki, 
G.; Mizumura, M.; Sugiyama, H. Bioorganic & Medicinal Chemistry 2007, 15 
(22), 6937. 
(97) Shibata, T.; Nakatani, K. ChemBioChem 2016, 17 (18), 1685. 
(98) Wong, C.-H. DEVELOPING POTENTIAL DRUGS FOR THE TREATMENT OF 
MYOTONIC DYSTROPHY: FROM RATIONAL DESIGN TO LEAD 
DEVELOPMENT, 2013, pp 1–123. 
(99) Arambula, J. F. PART I. A STACKED INTERCALATOR APPROACH TO 
SELECTIVELY TARGET MISMATCHES WITHIN CTG AND CUG 
TRINUCLEOTIDE REPEATS. PART II. AROMATIC STACKING OF 
NAPHTHOYL MODIFIED CYTOSINES WITHIN PNA•DNA DUPLEXES, 
2010, pp 1–168. 
(100) Constant, J. F.; Laûgaa, P.; Roques, B. P.; Lhomme, J. Biochemistry 1988, 27 (11), 
3997. 
(101) Fkyerat, A.; Demeunynck, M.; Constant, J. F.; Michon, P.; Lhomme, J. J. Am. 
Chem. Soc. 1993, 115 (22), 9952. 
(102) Alarcon, K.; Demeunynck, M.; Lhomme, J.; Carrez, D.; Croisy, A. Bioorganic & 
Medicinal Chemistry 2001, 9 (7), 1901. 
(103) Wong, C.-H.; Fu, Y.; Ramisetty, S. R.; Baranger, A. M.; Zimmerman, S. C. 
Nucleic Acids Research 2011, 39 (20), 8881. 
(104) Leonard, N. J.; Lambert, R. F. J. Org. Chem. 1969, 34 (11), 3240. 
 114 
(105) Rewcastle, G. W.; Denny, W. A. Synthetic Communications 1987, 17 (3), 309. 
(106) Leonard, N. J. Acc. Chem. Res. 1979, 12 (12), 423. 
(107) Peyret, N.; Seneviratne, P. A.; Allawi, H. T.; SantaLucia, J., Jr. Biochemistry 1999, 
38 (12), 3468. 
(108) Rojsitthisak, P.; Romero, R. M.; Haworth, I. S. Nucleic Acids Research 2001, 29 
(22), 4716. 
(109) Kaul, M.; Pilch, D. S. Biochemistry 2002, 41 (24), 7695. 
(110) Hayatsu, H.; Ukita, T. Biochem. Biophys. Res. Commun. 1967, 29 (4), 556. 
(111) Nakatani, K.; Sando, S.; Kumasawa, H.; Kikuchi, J.; Saito, I. J. Am. Chem. Soc. 
2001, 123 (50), 12650. 
(112) Vögtle, F.; Pawlitzki, G.; Hahn, U. In Modern Cyclophane Chemistry; 2005; pp 
41–80. 
(113) Cram, D. J.; Cram, J. M. Acc. Chem. Res. 1971, 4 (6), 204. 
(114) Lehn, J.-M.; Schmidt, F.; Vigneron, J.-P. Tetrahedron Letters 1988, 29 (41), 5255. 
(115) Jazwinski, J.; Blacker, A. J.; Lehn, J.-M.; Cesario, M.; Guilhem, J.; Pascard, C. 
Tetrahedron Letters 1987, 28 (48), 6060. 
(116) Ramaiah, D.; Neelakandan, P. P.; Nair, A. K.; Avirah, R. R. Chem. Soc. Rev. 2010, 
39 (11), 4158. 
(117) Zimmerman, S. C.; Lamberson, C. R.; Cory, M. J. Am. Chem. Soc. 1989, 111 (17), 
6805. 
(118) Yang, X.-L.; Robinson, H.; Gao, Y.-G.; Wang, A. H.-J. Biochemistry 2000, 39 
(36), 10950. 
(119) Jourdan, M.; Garcia, J.; Lhomme, J.; Teulade-Fichou, M.-P.; Vigneron, J.-P.; Lehn, 
J.-M. Biochemistry 1999, 38 (43), 14205. 
(120) Mukherjee, S.; Dohno, C.; Asano, K.; Nakatani, K. Nucleic Acids Research 2016, 
gkw672. 
(121) Mukherjee, S.; Dohno, C.; Nakatani, K. Chem. Eur. J. 2017, 23 (47), 11385. 
(122) Goodell, J. R.; Madhok, A. A.; Hiasa, H.; Ferguson, D. M. Bioorganic & 
Medicinal Chemistry 2006, 14 (16), 5467. 
(123) de Hoog, P.; Gamez, P.; Driessen, W. L.; Reedijk, J. Tetrahedron Letters 2002, 43 
(38), 6783. 
 115 
(124) Baliani, A.; Bueno, G. J.; Stewart, M. L.; Yardley, V.; Brun, R.; Barrett, M. P.; 
Gilbert, I. H. J. Med. Chem. 2005, 48 (17), 5570. 
(125) Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; 
Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. J. Natl. Cancer Inst. 1990, 82 
(13), 1107. 
(126) Vichai, V.; Kirtikara, K. Nat Protoc 2006, 1 (3), 1112. 
(127) Cravatt, B. F.; Wright, A. T.; Kozarich, J. W. Annu. Rev. Biochem. 2008, 77 (1), 
383. 
(128) Mizoue, L. S.; Tellinghuisen, J. Analytical Biochemistry 2004, 326 (1), 125. 
 
